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INTRODUCTION 
 
Antimicrobial resistance is on the rise and it is a major public health 
problem across the world, especially in developing countries like India.1 The 
continuing emergence of resistant strains causing nosocomial infections 
contributes to the morbidity and mortality among hospitalized patients. Of the 
nosocomial pathogens, Pseudomonas aeruginosa and Acinetobacter baumannii 
are of greatest concern for patients admitted in intensive care units [ICU].2 
 
Surgical site infections, urinary tract infections, ventilator associated 
pneumonia and bacteremia are serious infections caused by them especially in 
critically ill and immunocompromised.3 Management of these infections is 
difficult, as many strains often develop intrinsic and acquired resistance to 
multiple classes of antimicrobial drugs.4 
 
Multi-drug resistant organisms (MDRO) are those organisms which are 
resistant to at least one agent in at least three antimicrobial classes of 
Cephalosporins, β-lactam/β-lactamase inhibitors, Carbapenems, 
Fluoroquinolones, Aminoglycosides.5 Various mechanisms for MDR include loss 
of outer membrane protein, overexpression of efflux pump, production of β-
lactam hydrolyzing enzymes such as extended spectrum β-lactamases (ESBL)& 
AmpC β-lactamases and carbapenem hydrolyzing enzymes (metallo-β-
lactamases, oxacillinase).6 
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The introduction of carbapenem antibiotics such as meropenem and 
imipenem into clinical practice was of great help in the treatment of serious 
infections caused by the ESBL and AmpC producing multidrug-resistant (MDR) 
bacteria.4 However, the resistance to these drugs is also on the rise because of 
emergence of metallo β-lactamases (MBL) and OXA type carbapenemases, which 
is seen predominantly in Acinetobacter baumannii.  
 
Globally, reports on the carbapenemase-producing non-fermenting Gram-
negative bacilli such as Pseudomonas aeruginosa and Acinetobacter baumannii 
are on the rise due to the increased carbapenem usage and selection pressure. In 
India, carbapenem resistance ranges from 10.9 - 69% in Pseudomonas aeruginosa 
and 9.1-100% in Acinetobacter baumannii has been reported among various 
patient populations in differet sample types, predominantly from respiratory 
specimens and pus samples.7,8,9,10 
 
 As the production of the carbapenem hydrolyzing enzymeis plasmid 
mediated, it limits the therapeutic options and is a matter of serious concern for 
infection control management.11 Therefore, early identification and detection of 
isolates that produce these enzymes are essential to avoid therapeutic failures and 
nosocomial outbreaks.3 World Health Organization (WHO) has categorized 
carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii as 
Priority 1- Critical organisms for the research and development of newer 
antibiotics.12 
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Colistin (Polymyxin E), was one of the earliest polymyxin antibiotics, used 
for the treatment of gram-negative bacterial infections; however, side effects such 
as nephrotoxicity, and the development of less toxic antibiotics, led to its 
withdrawal from general use. The appearance of multidrug resistant strains of 
A.baumannii and P. aeruginosa has once again led to the reconsideration of 
colistin for the treatment of carbapenem resistant gram-negative bacterial 
infections.1,13 Susceptibility testing for colistin should be carried out prior to 
administration to prevent treatment failure. 
 
There is enormous geographic variation in the prevalence of antimicrobial 
resistance; therefore the resistance profile of resistant strains requires enhanced 
monitoring, especially for selection of empirical antibiotic. Obtaining regional 
resistance data is important for establishing guidelines for appropriate antibiotic 
use, and may help to control the rate of antibiotic resistance.13 
 
In this background this study aims to determine the prevalence of 
carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii 
isolates among various clinical samples, to characterize the prevalent resistance 
mechanisms phenotypically and genotypically and to evaluate the in vitro 
susceptibility of colistin against the carbapenem resistant isolates. 
  
Aims & Objectives 
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AIMS AND OBJECTIVES 
 
 To isolate and identify Pseudomonas aeruginosa and Acinetobacter 
baumannii isolates from various samples. 
 
 To study the antimicrobial susceptibility pattern of the isolates. 
 
 To characterize the carbapenem resistant isolates phenotypically and 
genotypically. 
 
 To study the colistin susceptibility among carbapenem resistant isolates.  
 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
Pseudomonas aeruginosa 
Pseudomonads belong to the genus gammaproteobacteria, of family 
Pseudomonadaceae. Pseudomonads are aerobic, rod-shaped, gram-negative 
bacteria, motile by means of polar flagella. They are not acid-fast and do not form 
spores. The guanine and cytosine (G+C) content of the DNA ranges from 57 to 70 
mol%. The pseudomonads are non-exacting and grow normally using simple 
sources of carbon and nitrogen.14 The most important pseudomonads causing 
human infections are Pseudomonas aeruginosa, members of the Burkholderia 
cepacia complex and Burkholderia pseudomallei.15  
 
CLASSIFICATION OF MEDICALLY IMPORTANT  
PSEUDOMONADS16,17 
 Classification of pseudomonads is based on rRNA/DNA homology and 
cultural characteristics.  
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Table 1: Classification of medically important pseudomonads 
rRNA Homology group and 
subgroup Genus and species 
I    Fluorescent group 
 Non-fluorescent group 
Pseudomonas aeruginosa 
P.fluorescenes 
P.putida 
P.stutzeri 
P.mendocina 
II Burkholderia pseudomallei 
B.mallei 
B.cepacia 
Cupriavidus 
Delftia 
Pandoraea 
Ralstonia picketti 
III Comamonas species Acidovorax species 
IV Brevundimonas species 
V Stenotrophomonas maltophilia 
 
 Pseudomonas aeruginosa is the species most commonly associated with 
human diseases. There are several reasons for Pseudomonas aeruginosa acting as 
an opportunistic human pathogen: 
• adaptability 
• innate resistance to many antibiotics and disinfectants 
• putative virulence factors 
• increasing number of patients compromised by age, underlying disease or 
immunosuppressive therapy.15 
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MORPHOLOGY AND IDENTIFICATION 
MICROSCOPY 
 Pseudomonas aeruginosa is a motile rod shaped bacterium with single 
polar flagellum measuring about 0.5Χ 0.8 µm, and it is gram-negative.Mucoid 
strains may be distinguished on direct microscopic examination by the presence of 
clusters of short gram-negative bacilli surrounded by dark pink staining material 
(alginate).It is non-sporing and non-acid fast. Fimbriae may be present which are 
polar and non-haemagglutinating.6,16,18 
 
CULTURAL CHARACTERISTICS 
 P.aeruginosa is an obligate aerobe, grows readily on ordinary culture 
media, producing a sweet or grape like corn taco-like odour. Some strains are 
hemolytic. P.aeruginosa grows well at 37-42ºC; growth at 42ºC differentiates it 
from other pseudomonads in the fluorescent group (P.fluorescens, P.putida).16 
 
COLONY MORPHOLOGY 
P.aeruginosa in a solid culture mediaproduces various types of colonies. 
1. Circular, smooth, translucent, homogeneous, gray white colonies with 
entire edges. The consistency is soft. 
2. Irregular, contoured, translucent gray white colonies with “beaten copper 
appearance”. The consistency is soft. 
3. Dry, flat, opaque, granular, gray white colonies. The consistency is almost 
friable. 
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4. Mucoid, shining, whitish or grayish-green colonies; larger than other 
colony types. The consistency is soft, more or less viscid. 
5. Rugose, opaque, granular, gray white colonies. The surface is wrinkled, 
with irregular or radiant crests, and usually dry. The consistency is 
membranaceous.11 
 
PIGMENT PRODUCTION 
P.aeruginosa produces four types of water soluble (diffusible) pigments when 
grown on nutrient agar. 
1. Pyocyanin 
2. Pyoverdin (Fluorescein) 
3. Pyomelanin 
4. Pyorubin 
 
PYOCYANIN 
 Pyocyanin is a blue, non-fluorescent, water and chloroform soluble 
pigment, diffuses into the surrounding medium. It is produced exclusively by 
Pseudomonas aeruginosa.It is formed best in peptone media. When pyocyanin is 
produced in small amounts, or when its presence is obscured by other pigments, it 
can be observed by shaking a few milliliters of chloroform in a broth culture or an 
agar slope; on standing pyocyanin will appear in chloroform once the phases are 
separated (Chloroform extraction).18 
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PYOVERDIN 
 Pyoverdin is yellow, fluorescent water soluble pigment formed only in the 
presence of phosphate and chloroform insoluble. It is produced by all members of 
the fluorescent group. Pyoverdin is best observed when the cultures are 
illuminated by Ultra Violet (UV) light under a dark background. 
 
PYOMELANIN 
 It is a dark brown pigment produced by some strains of P.aeruginosa. 1% 
tyrosine enhances the production of pyomelanin. 
 
PYORUBIN 
 Few strains of P.aeruginosa produce a red colour pigment, Pyorubin. 
Growth in 1% DL-Glutamate enhances production of pyorubin.18 
 
 
Fig:1 P.aeruginosa on MacConkey agar – Mucoid non-lactose fermenting 
colonies 
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Fig:2 P.aeruginosa colonies on blood agar with metallic sheen 
 
BIOCHEMICAL REACTIONS 
Catalase – positive, oxidase – positive, reduces nitrate to nitrite and 
nitrogen gas, non-fermenter – oxidatively uses glucose, maltose and mannitol 
variable, dihydrolyses arginine, utilizes citrate as a sole source of carbon, utilizes 
acetamide, liquefies gelatin, urea hydrolysis – variable, do not produce H2S, 
sensitive to Polymyxin B 300U.17 
 
SENSITIVITY TO PHYSICAL & CHEMICAL AGENTS 
 P.aeruginosa is being killed at 55ºC in one hour, but exhibits a high degree 
of resistance to chemical agents. It is susceptible to acids, beta glutaraldehyde, 
silver salts and strong phenolic disinfectants.  It is resistant to common antiseptics 
and disinfectants such as chloroxylenol, quarternary ammonium salts, 
hexachlorophene and cetrimide.18,19 
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VIRULENCE FACTORS 
 Alginate – Capsular polysaccharide permitting infecting bacteria to adhere 
to lung epithelial cells and forms biofilms which protects the bacteria from 
the host immune system and antibiotics. 
 Pili – Surface appendages facilitating the adherence of organism to GM-1 
ganglioside receptor on host epithelial cell surface. 
 Neuraminidase – facilitates binding of pili by removing sialic acid 
residues from GM-1 ganglioside receptors 
 Lipopolysaccharide – Endotoxin; causes sepsis, fever, shock, leucopenia 
or leucocytosis, oliguria, disseminated intravascular coagulation and 
metabolic abnormalities. 
 Endotoxin A–causes tissue destruction by inhibiting protein synthesis, 
interrupting cell activity and macrophage response. 
 Enterotoxin – causes diarrhoea by interrupting normal gastro-intestinal 
activity. 
 Exoenzyme S – acts by inhibiting protein synthesis. 
 Phospholipase C – inactivates opsonins, destroys cytoplasmic membrane 
and pulmonary surfactant. 
 Elastase – disrupts neutrophil activity, cleaves immunoglobulin and 
complement components. 
 Leukocidin – inhibits lymphocyte and neutrophil function. 
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 Pyocyanin – suppresses other bacteria, disrupts respiratory ciliary activity 
and causes oxidative damage to tissues, particularly oxygenated tissues 
such as lung.17 
 
TYPING METHODS 
Typing of P.aeruginosa is useful for epidemiological typing to establish 
the origin of strains causing infections, and is very important to guide treatment in 
environments of limited dimensions. 
 Bacteriocin typing 
 Serological typing 
 
BACTERIOCIN TYPING 
 Bacteriocins are proteins produced by one strain of bacteria that are lethal 
against the cells of other strains of the same species. Pyocins are the bacteriocins 
produced by P.aeruginosa, used to classify P. aeruginosa. There are four 
categories of pyocins. 
1. R type – resembling the tail of bacteriophages 
2. F type - flexuous filaments 
3. Low molecular weight trypsin-sensitive S type 
4. Low molecular weight trypsin-resistant S type 
 
 Individual strains of Pseudomonas aeruginosa may produce more than one 
category of pyocin and also possess receptors for several different pyocins. 
Individual pyocins can be recognised based on their spectrum of activity against 
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different strains of P.aeruginosa. The pyocin produced by an unknown strain of 
P.aeruginosa is tested against a series of indicator strains.14,18 
 
SEROLOGICAL TYPING 
 Serological typing is mainly used for epidemiological purpose. Nineteen 
group specific, heat stable O antigens and two heat labile H antigens have been 
recognized based on slide agglutination test.14,18 
 
CLINICAL SIGNIFICANCE 
 P. aeruginosa causes both localized and systemic illness. Any tissue or 
organ system may be affected. Individuals who are at risk include those with 
impaired immune defenses. 
 
1. LOCALIZED INFECTIONS  
 Eye infections such as keratitis and endophthalmitis following trauma 
 Ear infections causing external otitis, or swimmer's ear, and invasive and 
necrotizing otitis externa (malignant otitis externa) particularly in older 
diabetic patients 
 Skin infections such as wound infection and pustular rashes 
 Urinary tract infections particularly in hospitalized patients due to 
catheterization, instrumentation, surgery, or renal transplantation 
 Respiratory tract infections causing pneumonia in individuals with chronic 
lung disease, congestive heart failure, or cystic fibrosis, particularly in 
patients who have been intubated or are on ventilators for longer period 
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 Gastrointestinal tract infections ranging from mild diarrheal illness in 
children to severe, necrotizing enterocolitis in infants and neutropenic 
cancer patients  
 CNS infections causing meningitis and brain abscesses 
 
 Localized infections have the potential to lead to disseminated infection in 
immunocompromised individuals.20 
 
2. SYSTEMIC INFECTIONS 
Infections indicating systemic spread of the organism include bacteremia 
(most common in immunocompromised patients), secondary pneumonia, bone 
and joint infections (in intravenous drug users and patients with urinary tract or 
pelvic infections), endocarditis (in intravenous drug users and patients with 
prosthetic heart valves), central nervous system CNS (when the meninges are 
breached), and skin and soft tissue infections.20 
 
P. aeruginosa is feared because it can cause severe nosocomial infections, 
especially in immunocompromised hosts. Often it is resistant to many antibiotics 
limiting the treatment option. 
 
MECHANISM OF ANTIMICROBIAL RESISTANCE 
Pseudomonas aeruginosa has two main mechanisms of resistance 
 Intrinsic resistance 
 Acquired resistance 
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INTRINSIC RESISTANCE 
 Intrinsic resistance is defined as the innate or inherent antimicrobial 
resistance, which is reflected in wild type antimicrobial patterns of all or almost 
all representatives of a species. Intrinsic resistance is so common that the 
susceptibility testing is unnecessary. It is mainly due to over expression of efflux 
pumps (mexAB, mexCD, mexEF and mexXY), inducible chromosomal hyper 
ampC production and loss of porins (oprD).6,21 
  
Pseudomonas aeruginosa is intrinsically resistant to amoxicillin, 
ampicillin, ampicillin-sulbactam, amoxicillin-clavulanate, cefotaxime, 
ceftriaxone, ertapenem, trimethoprim-sulfamethoxazole, tetracycline, and 
chloramphenicol.21 
 
EXTRINSIC RESISTANCE 
 This is the acquired resistance to an antimicrobial agent due to the 
acquisition of genes coding for resistance. Acquired resistance is due to 
 
 Over use and misuse of an antibiotic is the most common cause. 
 Evolution of strains is a natural phenomenon, which can occur among 
bacteria when an antibiotic is over used. 
 Use of particular antibiotic poses selective pressure in a population of 
bacteria which promotes resistant bacteria to thrive and the susceptible 
bacteria to die off. 
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This is of importance as the resistant strains which can tolerate harsh 
environments, then spread in the environment and transfer the genes coding for 
resistance to other unrelated bacteria.22 
 
 Extrinsic mechanisms include acquisition of resistance genes such as 
extended spectrum beta-lactamases (blaSHV, blaTEM, blaVEB, blaPER) and 
carbapenemases (blaVIM, blaNDM, blaIMP, blaKPC, blaSPM).1 
 
Table 2: CLASSIFICATION OF BETA-LACTAMASES6,17 
Bush-Jacoby  
classification 
(2010) 
Ambler 
Molecular 
class 
Enzymes Active site 
Enzyme 
inhibitors Found in 
Group 1 
Cephalosporinase C 
AmpC, 
ACT-1, 
CMY-2, 
FOX-1, 
MIR-1 
Serine PBA, DPA, Cloxacillin 
Enterobacteriaceae, 
Acinetobacter spp. 
Group 1e 
Cephalosporinase C 
GC1, 
CMY-37 Serine 
Not 
inhibited by 
CV or PTZ 
Enterobacteriaceae 
Group 2a 
Penicillinases A PC1 Serine CV or PTZ 
Staphylococcus 
aureus 
Group 2b 
Penicillinases A 
TEM-1, 
TEM-2, 
SHV-1 
Serine CV or PTZ Enterobacteriaceae 
Group 2be ESBL A 
TEM-3, 
SHV-2, 
CTX-Ms, 
PER-1, 
VEB-1 
Serine CV or PTZ 
Escherichia coli, 
Klebsiella 
pneumoniae, 
K.oxytoca, Proteus 
mirabilis, 
Salmonella spp. 
Group 2 ber ESBL A TEM-50 Serine 
Not 
inhibited by 
CV or PTZ 
Enterobacteriaceae 
Group 2 d D OXA-01, OXA-10  
Variable 
with CV or 
PTZ 
Enterobacteriaceae 
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Bush-Jacoby  
classification 
(2010) 
Ambler 
Molecular 
class 
Enzymes Active site 
Enzyme 
inhibitors Found in 
Group 2 de ESBL D OXA-11, OXA-15 Serine 
Variable 
with CV or 
PTZ 
P.aeruginosa 
Group 2 df 
Carbapenemase D 
OXA-23, 
OXA-48 Serine 
Variable 
with CV or 
PTZ 
Acinetobacter 
baumannii 
Enterobacteriaceae 
Group 2e ESBL A CepA Serine CV but not Aztreonam Proteae 
Group 2f 
Carbapenemase A 
KPC-2, 
SME-1, 
IMI-1 
Serine 
Variable 
with CV or 
PTZ 
Enterobacteriaceae 
Group 3 Metallo- 
carbapenemase B 
IMP-1, 
VIM-2, 
IND-1, 
L1 
Zinc EDTA P.aeruginosa, A.baumannii 
Group 4 Not included Unknown 
 
PBA- Phenyl Boronic Acid  DPA- Di picolinic Acid CV- Clavulanic acid 
PTZ- Piperacillin-Tazobactam EDTA- Ethylene Diamine Tetra Acetate 
 
 Extended spectrum beta-lactamases (ESBL) and AmpC beta-lactamases are 
capable of hydrolyzing cephalosporins. ESBL belongs to Class A beta-lactamase 
of Ambler molecular classification while AmpC beta-lactamase belongs to 
ClassC. Carbapenems, β-lactams and β-lactamase inhibitor combinations such as 
piperacillin-tazobactam are the drugs active against ESBL and AmpC producing 
Pseudomonas aeruginosa isolates.  
 
 Nowadays, there is increased resistance to these drugs because of the 
emergence of metallo β-lactamases (MBL). In Pseudomonas aeruginosa, the 
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carbapenem resistance is predominantly mediated by metallo β-lactamases. These 
enzymes belong to Class B β-lactamase of Ambler classification. These enzymes 
can hydrolyse all classes of β-lactam antibiotics with the exception of 
monobactams (Aztreonam) and resist neutralization by β-lactamases inhibitor 
antibiotics.11 
 
Plasmid mediated MBL genes spread rapidly to other species of gram-
negative bacilli. In recent years, MBL genes have spread from P. aeruginosa to 
Enterobacteriaceae, and a clinical scenario appears to be developing that could 
simulate the global spread of extended-spectrum beta-lactamases. It is known that 
poor outcome occurs when patients with infections due to metallo β-lactamase 
producing organisms are treated with antibiotics to which the organism is 
completely resistant.23  Hence, rapid detection of metallo β-lactamase production 
is important to modify therapy and to initiate effective infection control in 
preventing their dissemination.24  
 
Acinetobacter baumannii 
Acinetobacter species are ubiquitous, aerobic gram-negative bacteria that 
are widely distributed in soil and water and can be cultured from skin, mucous 
membranes, secretions, and the hospital environment. Acinetobacters often are 
commensals but cause nosocomial infection in immunocompromised patients.  
 
Acinetobacter baumannii is the most commonly isolated species of clinical 
importance. A.baumannii has been isolated from various clinical specimens such 
as blood, sputum, skin, pleural fluid, and urine, usually in device-associated 
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infections. Acinetobacter lwoffii, Acinetobacter johnsonii, Acinetobacter 
haemolyticus are the other Acinetobacter species of low significance.16  
 
CLASSIFICATION OF ACINETOBACTER SPECIES17,22 
 Acinetobacter baumannii belongs to the family Moracellaceae. Based on 
DNA hybridization, Acinetobacter species can be grouped into several 
genomospecies up to 25 types. 
 
Table 3: Classification of Acinetobacter species 
Genomospecies Current designation 
1 A.calcoaceticus 
2 A.baumannii 
3 A.pittii 
4 A.haemolyticus 
5 A.junii 
6 Unnamed 
7 A.johnsonii 
8/9 A.lwoffii 
10 A.bereziniae 
 
MORPHOLOGY AND IDENTIFICATION 
MICROSCOPY 
 They are strictly aerobic short, stout gram-negative coccobacilli, arranged 
singly or in pairs often appearing as diplococco-bacilli. Often they are gram-
positive and gram variable; non-motile, non-sporing and some strains are 
capsulated.17,18 
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CULTURAL CHARACTERISTICS 
 On nutrient agar, after 24 hours the colonies are white or cream coloured, 
smooth, circular of 0.5 to 2 mm in diameter, translucent to opaque, convex with 
entire edges and never pigmented. On MacConkey agar, most strains grow well 
and produce a faint pink tint. The colonies are non-hemolytic on blood agar. 
Growth at 42ºC is a feature differentiating A.baumannii from A.lwoffii.17,18 
 
 
  
Fig:3 Colonies of A.baumannii on MacConkey agar –  
Non-lactose fermenter with pink tint 
 
BIOCHEMICAL REACTIONS  
 Catalase positive, oxidase negative, non-fermenting coccobacilli; 
saccharolytic - acidifies carbohydrates oxidatively (glucose, lactose), oxidatively 
uses 10% lactose (Hugh-Leifson’s oxidation fermentation media), utilizes citrate, 
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indole negative, do not reduce nitrates to nitrite, some strains produce urease, 
dihydrolyses arginine.14,17,18  
 
PATHOGENESIS 
HOSPITAL ADAPTIVENESS 
 The role of the hospital environment as a reservoir for A. baumannii is 
supported by the fact that this organism can be recovered from patients and 
various hospital environmental sources during outbreaks. A number of studies 
show that particular strains can be isolated from the same hospital during a long 
period of time. The ability to survive under desiccative conditions as well as 
resistance to disinfectants and antimicrobials demonstrate how well A. baumannii 
can adapt and lead to long term persistence in the hospital environment.25 
 
Table 4: Putative genes for hospital adaptiveness 
Name of gene or protein Function 
csuC and csuE Secretion and pili assembly Biofilm formation 
blaPER-1 
 β-lactamase production 
Associated with cell adhesiveness 
Bap Intercellular adhesion Biofilm maturation 
pga PNAG synthesis – adhesin for maintenance of biofilm structural stability 
 
csuC, csuE – Chaperone-usher pili assembly system  
blaPER-1 – Pseudomonas Extended Resistant β-lactamase 
Bap – biofilm associated protein gene 
pga– poly-β-1,6- N-acetyl Glucosamine gene 
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VIRULENCE FACTORS16,17 
Usually acinetobacters are not pathogenic, but they do have components 
that are capable of enhancing their virulence in debilitated individuals. 
 
 Endotoxin - Endotoxin is a lipopolysaccharide (LPS) moiety in the outer 
membrane, in which the toxic lipid component, lipid A, is embedded. It 
induces inflammatory response that leads to tissue injury and responsible 
for the febrile response during septic episodes. 
 Outer membrane protein A (OmpA) – mediates adhesion, invasion and 
cytotoxicity through mitochondrial damage. 
 Fimbriae - capable of facilitating adhesion to human epithelial cells. 
 Polysaccharide capsule – core virulence factor which limits the 
phagocytosis, aids the bacterium to survive under dry conditions. 
 Siderophores and iron-repressible outer membrane receptor proteins - 
The ability of A. baumannii to grow under iron-deficient conditions is 
known to be associated with invasiveness. 
 Quorum sensing and biofilm formation 
 
CLINICAL SPECTRUM OF INFECTIONS 
 Acinetobacter baumannii is an environmental bacterium and has been 
isolated from opportunistic infections such as pneumonia, bacteraemia, 
meningitis, endocarditis, burn wound sepsis, urinary tract, eye and bone 
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infections. It is mostly associated with nosocomial infections, however 
community acquired infections has also been reported.  
 
 The risk factors include long term hospitalization in ICU (Intensive Care 
Unit), use of antibiotics, use of invasive diagnostic and therapeutic procedures, 
immunocompromised diseases, use of steroids,   major surgery, burns, malignancy 
and severe underlying diseases. A.baumannii infections are mainly centered in the 
ICUs like respiratory, neurosurgical, neonatal and burns. Most common 
nosocomial infection include Ventilator associated pneumonia (VAP), Central 
line associated blood stream infections (CLABSI), Catheter associated urinary 
tract infections (CAUTI) and Surgical site infections (SSI).14,17,26 
 
MECHANISM OF ANTIBIOTIC RESISTANCE 
Acinetobacter baumannii is relatively resistant to almost all the available 
drugs and increased antimicrobial resistance has been implicated in nosocomial 
infections and hospital outbreaks.1 Acinetobacter baumannii is intrinsically 
resistant to many antimicrobial agents like ampicillin, amoxicillin, amoxicillin-
clavulanate, aztreonam, ertapenem, trimethoprim, chloramphenicol and 
fosfomycin.21 
 
Unlike Pseudomonas aeruginosa, antimicrobial resistance in Acinetobacter 
baumannii is predominantly through acquired resistance mechanisms such as 
production of ESBL, Class A carbapenemases(blaSHV, blaTEM, blaGES,blaKPC), 
Class B metallo β-lactamases (MBL – blaNDM, blaVIM, blaIMP), Class C β-
24 
 
 
lactamases (Acinetobacter derived cephalosporinases) and the most common 
Class D β-lactamases (blaOXA-23 like, blaOXA-24 like, blaOXA-51 like,blaOXA-58 like).  
 
Non-enzymatic mechanisms such as membrane impermeability by either 
loss of or decrease in expression of outer membrane proteins (CarO) or an 
increased expression of efflux pumps (AdeABC) also contributes to antimicrobial 
resistance in Acinetobacter baumannii.1  
 
CARBAPENEM  
HISTORICAL BACKGROUND 
In the late 1960, as bacterial β-lactamases emerged and threatened the use 
of penicillin, the search for β-lactamase inhibitors began.  By 1976, the first β-
lactamase inhibitors were discovered; these were natural products produced by the 
Gram-positive bacterium Streptomyces clavuligerus. This was followed by the 
discovery of thienamycin in 1976, produced by Streptomyces cattleya. The term 
“Carbapenem” is defined as the 4:5 fused ring lactam of penicillins with a double 
bond between C-2 and C-3 but with the substitution of carbon for sulfur at C1.27,28 
 
Thienamycin, an unstable carbapenem had inhibitory microbiological 
activity against Gram-negative bacteria, including Pseudomonas aeruginosa, 
anaerobes likes Bacteriodes fragilis and Gram-positive bacteria. Hence, years 
later, a more stable thienamycin derivative, known as Imipenem, was synthesized 
and approved for use in 1984. It became the first carbapenem approved for the 
treatment of complex microbial infections.27,28,29 
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However, imipenem was susceptible to deactivation by dehydropeptidase -
1 (DHP-1), found in the human renal brush border. Therefore, co-administration 
with an inhibitor, cilastatin or betamipron in the ratio of 1:1 with imipenem 
prevented hydrolysis by DHP-1 and reduced nephrotoxicity. Along the journey to 
the discovery of more-stable carbapenem with extended spectrum, the other 
currently available compounds such as meropenem, biapenem, ertapenem, and 
doripenem were developed with the addition of a methyl group to the 1-β position. 
Meropenem was the first carbapenem with the 1-β-methyl group which renders 
this antibiotic stable to DHP-1.27,30 
 
CLASSIFICATION 
Carbapenems are classified into three groups.  
 Group 1 Carbapenems are defined as broad-spectrum agents that have 
limited/no activity against non- fermentative Gram-negative bacilli 
(NFGNB) and are most suited for use in treating infections caused by 
Enterobacteriaceae - e.g. Ertapenem.  
 Group 2 Carbapenems are broad-spectrum agents that are active against 
NFGNB and are particularly useful in treating nosocomial infections – e.g. 
Imipenem, Meropenem, Doripenem. 
 Group 3 Carbapenems which include agents with activity against 
methicillin-resistant Staphylococcus aureus (MRSA), such as Razupenem 
(PZ-601).27,31 
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MECHANISM OF ACTION 
 Carbapenems act by inhibiting the synthesis of the peptidoglycan layer of 
the bacterial cell wall. Carbapenems are not easily diffusible through the bacterial 
cell wall. Carbapenems enter Gram-negative bacteria through outer membrane 
proteins (OMP), also known as porin proteins. Carbapenems act by inhibiting 
peptide cross-linking as well as other peptidase reactions. Thereby, the 
peptidoglycan weakens, and the cell bursts due to osmotic pressure.28,29,32 
 
ACTIVITY OF CARBAPENEMS 
Carbapenems have a broad spectrum of antimicrobial activity and are 
rapidly bactericidal agents because they bind with high affinity PBPs of Gram-
negative bacteria. Carbapenems are the drug of choice for the treatment of 
infections caused by ESBL producing Enterobacteriaceae. Carbapenems (except 
ertapenem) are active against clinically significant gram-negative non-fermenters 
such as P. aeruginosa, Burkholderia cepacia and Acinetobacter spp. They also 
retain activity against streptococci, methicillin-sensitive staphylococci, Neisseria 
and Haemophilus.27,33  
 
Unlike most other broad-spectrum antibiotics, carbapenems are active 
against most Gram-positive and Gram-negative anaerobes. Carbapenem-resistant 
bacteria include ampicillin-resistant Enterococcus faecium, methicillin-resistant 
Staphylococci, Stenotrophomonas maltophilia and some isolates of Clostridium 
difficile.27,33 
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CARBAPENEM RESISTANCE 
Carbapenems are the drugs of choice in the treatment of infections caused 
by multidrug resistant P. aeruginosa and A. baumannii. Emergence and spread of 
carbapenem resistance limits therapeutic options to polymyxins and tigecycline. 
Resistance to carbapenems is mediated by lack of drug penetration (i.e., porin 
mutations and efflux pumps) and / or carbapenem hydrolysing beta lactamase 
enzymes (carbapenemases).  
 
PREVALENCE OF CARBAPENEM RESISTANCE 
The rates of carbapenem resistance in glucose non-fermenting gram-
negative bacilli have been gradually increasing worldwide over the last 10 years 
and vary geographically. The highest burden of carbapenem resistance among 
gram-negative healthcare associated infections in the US as reported by the 
NHSN from 2009-2010 was observed 86 among A. baumannii (62.6%) and P. 
aeruginosa (26.1%) in comparison to CRE where carbapenem resistance was 
highest among Klebsiella pneumoniae at 12.8%.34,35 In India, carbapenem 
resistance ranges from 10.9 - 69% in Pseudomonas aeruginosa and 9.1-100% in 
Acinetobacter baumannii has been reported among various patient populations in 
different sample types, predominantly from respiratory specimens and pus 
samples.7,8,9,10 
 
Carbapenem resistant P.aeruginosa infection not only increase mortality, 
but it is also associated with increased morbidity. Carbapenem–resistant 
Acinetobacter baumannii infection usually occurs in severely ill patients in the 
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ICU, therefore the associated crude mortality rate is high. Crude mortality rates of 
30 - 75% have been reported for nosocomial pneumonia caused by A. baumannii. 
 
CARBAPENEM RESISTANCE IN PSEUDOMONAS AERUGINOSA 
Carbapenem resistance mechanisms in P.aeruginosa include 
1. Production of carbapenem hydrolyzing enzymes (carbapenemases) 
2. Increased production of Amp C chromosome encoded cephalosporinases 
3. Reduced outer membrane porin – Opr D expression 
4. Overexpression of efflux pumps 
 
CARBAPENEMASES IN PSEUDOMONAS AERUGINOSA 
Carbapenemases mediating carbapenem resistance in Pseudomonas 
aeruginosa belong to Ambler Class A and Class B β-lactamases. 
 
Class A carbapenamases in P. aeruginosa  
The first report of KPC-producing P. aeruginosa isolates was described in 
three genetically related isolates from Colombia in 2007. The spread of blaKPC 
into different genera is most likely due to its presence within mobile genetic 
elements on plasmids of various sizes36.  
 
Class B metallo beta-lactamases in P. aeruginosa 
In general, carbapenem resistance in P. aeruginosa attributed to β-
lactamases is due to MBL. Production of MBL by P. aeruginosa leads to 
resistance to all betalactams except the monobactams such as aztreonam. The 
most common MBL families include the VIM, IMP, NDM, SPM, GIM and SIM 
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enzymes, which are located within a variety of integron structures, where they 
have been incorporated as gene cassettes. When these integrons become 
associated with plasmids or transposons, transfer of this resistance between 
bacteria is readily facilitated.  
 
Since their initial discoveries, SPM, GIM, and SIM metallo-β-lactamases 
have not spread beyond their countries of origin. However, VIM and IMP 
continue to be detected worldwide, with an overall trend of these two MBLs 
moving beyond P. aeruginosa and into the Enterobacteriaceae. The prevalence of 
MBL in India has ranged from 7% to 65% among carbapenem-resistant 
P.aeruginosa and bla VIM type was the most common.36  
 
EFFLUX MEDIATED CARBAPENEM RESISTANCE IN P. AERUGINOSA 
Active efflux is an important non-enzymatic mechanism of β-lactam 
resistance in P. aeruginosa. Efflux also contributes to the development of multiple 
resistances to all antipseudomonal antibiotics and is mediated by four genetically 
different three component efflux systems that belong to the resistance–
nodulation–division (RND) family: MexA–MexB–OprM, MexC–MexD–OprJ, 
MexE–MexF–OprN and MexX–MexY–OprM.37 
 
PORIN DEFECTS IN PSEUDOMONAS AERUGINOSA 
Loss of the OprD porin in P. aeruginosa is an important mechanism 
associated with imipenem resistance. The P. aeruginosa porin Opr D is a 
substrate-specific porin that has been shown to facilitate the diffusion of basic 
amino acids, small peptides that contain these amino acids, and carbapenems into 
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the cell. Loss of Opr D production is likely due to inactivation of the Opr D gene. 
Loss of Opr D does not confer resistance to β-lactams other than the carbapenems. 
Mutational loss of Opr D is frequent during Imipenem therapy. 
 
 The impact of Opr D deficiency on the potency of these carbapenems does 
not always push the MICs above the susceptible breakpoint, and additional 
resistance mechanisms (efflux pump and/or carbapenemase) may be required to 
provide resistance to the carbapenems.37,38 
 
CARBAPENEM RESISTANCE IN ACINETOBACTER BAUMANNII 
Carbapenem resistance in A. baumannii is due to a variety of combined 
mechanisms such as hydrolysis by β lactamases, alterations in outer membrane 
protein and penicillin binding proteins and increased activity of efflux pumps. 
 
CARBAPENEMASES IN ACINETOBACTER BAUMANNII 
Of the β-lactamases, those with carbapenemase activity are most 
concerning and include the serine oxacillinases (Ambler class D OXA type) and 
the MBLs (Ambler class B). These carbapenemases are of greatest concern as 
they are encoded by genes which are transmissible. 
 
OXA Carbapenemases in Acinetobacter baumannii 
The first identified OXA type enzyme with carbapenem hydrolysing 
activity was from A.baumannii strain isolated in 1985 from Scotland and was 
originally named ARI (Acinetobacter Resistant to Imipenem),but was renamed as 
bla OXA -23. Bla OXA -23 cluster (bla OXA -23,27,49) now contribute to carbapenem 
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resistance in A. baumannii globally. The bla OXA-23, bla OXA-24 and bla OXA-58 like 
enzymes are plasmid / chromosomally encoded which explains their widespread 
distribution.26,39 
 
The bla OXA-51 -like gene cluster is unique in that it is naturally occurring in 
A.baumannii. Similar to other class D enzymes, they have greater affinity for 
imipenem than meropenem. Their role in carbapenem resistance is related to the 
presence of an insertion sequence ISAba1, situated upstream possibly providing a 
promoter for hyper production of beta lactamase genes.40  
 
Class B Metallobetalactamase in Acinetobacter baumannii 
IMP-like, VIM-like, SIM-1 and NDM are the MBLs identified in A. 
baumannii. The IMP and VIM variants confer a high level of carbapenem 
resistance in A. baumannii.  
 
NON ENZYMATIC MECHANISMS IN ACINETOBACTER BAUMANNII 
β-lactam resistance, including carbapenem resistance, has also been 
ascribed to non-enzymatic mechanisms, including changes in outer membrane 
proteins, multidrug efflux pumps, and alterations in the affinity or expression of 
penicillin binding proteins (PBP).41 
 
Outer membrane proteins 
 A. baumannii possesses OMPs that play a role in carbapenem resistance. 
By reduction of transport into the periplasmic space via changes in porins or 
OMPs, access to PBP is reduced. With less β-lactam entering the periplasmic 
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space, the weak enzymatic activity of the β-lactamase is amplified. Many 
outbreaks of infection with imipenem-resistant A. baumannii are due to porin loss. 
Quale et al. found that carbapenem-resistant isolates of A. baumannii had reduced 
expression of 47-, 44-, and 37-kDa OMPs.41 
 
Efflux pump in Acinetobacter baumannii 
The resistance-nodulation-division (RND) family-type pump AdeABC is 
the best studied thus far and has a substrate profile that includes β-lactams 
(including carbapenems), aminoglycosides, erythromycin, chloramphenicol, 
tetracyclines, fluoroquinolones and trimethoprim. AdeABC has a three-
component structure: AdeB forms the trans-membrane component, AdeA forms 
the inner membrane fusion protein, and AdeC forms the OMP. AdeABC is 
chromosomally encoded.26,42  
 
PBP in Acinetobacter baumannii 
Modification of PBPs as a source of imipenem resistance in A. baumannii 
has been investigated only rarely.43 
 
TREATMENT  
Of the 6 famous ESKAPE pathogens (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter species, 
Pseudomonas aeruginosa, and Enterobacter species), P.aeruginosa and 
A.baumannii are the predominant pathogens causing nosocomial infections. 
World Health Organization (WHO) has categorized Carbapenem resistant 
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Pseudomonas aeruginosa and Acinetobacter baumannii as Priority 1- Critical 
organisms for the research and development of newer antibiotics.12 
 
Recognizing carbapenemase expression is the key to the appropriate 
management of infections caused by carbapenem-resistant isolates. Unusually 
elevated MICs to carbapenems should arouse suspicion for a carbapenem-resistant 
isolate and preclude the use of carbapenems even if the MICs do not exceed the 
breakpoints for resistance. As with ESBL-producing organisms, carbapenemase-
producing strains are likely to exhibit simultaneous resistance to aminoglycosides 
and fluoroquinolones. 
 
ANTIBIOTICS OF CHOICE 
Aztreonam 
It is stable to metallo-carbapenemases, including IMP, VIM and NDM. 
However, for isolates that also co-produce AmpC or ESBL, aztreonam is 
ineffective.44 
 
Sulbactam 
 Sulbactam is active against A.baumannii by inhibiting PBP-2. In most 
countries it is available as a co-formulation with ampicillin. Sulbactam is useful in 
the treatment of carbapenem resistant A.baumannii infections in combination with 
colistin.45 
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Tigecycline 
 Tigecycline, a tetracycline analogue is the first glycylcycline to be 
launched for clinical use. It acts by inhibiting the protein synthesis in the bacterial 
cell by binding to the 30S subunit of the ribosome. Its capacity to penetrate into 
various tissues makes it useful in the treatment of infections of the skin and soft 
tissues as well as intra-abdominal infections, whereas its low serum 
concentrations compromise its use in bloodstream infections. It is not useful in 
treatment of nosocomial pneumonia as indicated by poor results in the study of 
ventilator associated pneumonia. It is affected by the intrinsic multidrug efflux 
pumps of P.aeruginosa. Therefore, not useful in the treatment of infections caused 
by P.aeruginosa.45 
 
Polymyxin 
Given limited therapeutic options, clinicians have returned to the use of 
polymyxin B or polymyxin-E (colistin) for the most carbapenem resistant gram-
negative infections. Polymyxin B differs from colistin by only one aminoacid. 
These drugs act by disturbing the bacterial cell membrane, thus increasing 
permeability, leading to cell death.26,46,47  
 
Fosfomycin 
Fosfomycin inhibits bacterial cell wall synthesis, thereby exhibiting 
bactericidal activity against gram-positive and gram-negative pathogens. 
Fosfomycin is useful for the treatment of uncomplicated urinary tract infections at 
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a single oral dose. The emergence of resistance among GNB has sparked new 
interest in using fosfomycin to treat infections caused by MDR isolates.26,46,47 
 
Extended-Infusion Strategy for β-Lactams 
Carbapenems have also been evaluated in extended-infusion regimens. 
Lengthening meropenem infusions from 30 minutes to 3 hours was found to be 
advantageous with isolates of P. aeruginosa and A.baumannii with intermediate 
resistance. This benefit was not observed with resistant isolates having very high 
MIC.26,46,47 
 
Combination of a carbapenem with another active agent, preferentially an 
aminoglycoside or colistin could lower mortality provided that the Minimum 
Inhibitory Concentration of carbapenem for the infecting organism is up to 4 
µg/ml – and up to 8 µg/ml and the drug is administered in a high-dose/prolonged-
infusion regimen. In cases where the MICs for carbapenems are not available or 
are higher than 8 µg/ml, this class of drugs should not be used as part of a 
combination regimen to avoid further selection of resistance. 
 
INFECTION PREVENTION MEASURES 
Centre for Disease Control and prevention (CDC) recommendations for 
preventing transmission of Carbapenem resistant organisms include 
 
Laboratory detection of Carbapenem resistance  
 Accurate detection of carbapenem resistance is the first step in prevention. 
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Recognizing Carbapenem resistance cases 
It is important for health care facilities to understand how far carbapenem 
resistance is prevalent in their institutions. In the investigations conducted by the 
CDC, failure in recognizing carbapenem resistant infections when they first occur 
has resulted in a missed opportunity to intervene before these organisms are 
transmitted more widely.  
 
Based on the current recommendations for the control of multidrug-
resistant organisms (MDROs), in areas where carbapenem resistant organisms are 
not endemic, acute care facilities review microbiology records for the preceding 
6–12 months to determine whether carbapenem resistant organisms have been 
isolated at the facility. If previously unrecognized cases are identified, a round of 
surveillance cultures (i.e., a point prevalence survey) in high-risk areas (e.g., ICUs 
or wards where previous cases have been detected) should be considered to 
identify unrecognized cases.  
 
In addition, facilities should ensure a system is in place to notify infection 
control team when carbapenem resistant organisms are identified in the 
laboratory. All identified carbapenem resistant organisms case-patients should be 
placed on contact precautions, and patient cohorting and use of dedicated staff is 
also recommended for these patients.26,48 
 
Surveillance cultures 
If previously unrecognized carbapenem resistant cases or hospital-onset 
infections are identified via either clinical cultures or point prevalence surveys, 
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facilities should consider surveillance cultures from patients with epidemiologic 
links to carbapenem resistant case-patients.  
 
The goal of these cultures is to identify patients colonized with additional 
unrecognized carbapenem resistant organisms who are a potential source for 
transmission.26,48  
 
Antimicrobial Stewardship and minimizing devices 
Antimicrobial stewardship is an important part of efforts to control 
MDROs. However, multiple antimicrobial classes have been identified as possible 
risk factors for infection or colonization with carbapenem resistant organisms. 
Therefore, antimicrobial stewardship will be most effective if efforts are directed 
toward an overall decrease in antimicrobial use rather than targeting a specific 
antimicrobial class. Limiting use of invasive devices is another important 
intervention for prevention.26,48 
 
Antibiotic cycling 
 Antibiotic cycling or rotation is the scheduled substitution of a class of 
antibiotics with a different class that exhibits a comparable spectrum of activity. 
This substitution may be followed after a fixed interval by any number of 
substitutions but the cycle must be repeated with re-introduction of the original 
class/drug. The duration of each cycle is based on either local susceptibility 
patterns or a predetermined time period.49  
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Prevention beyond Acute Care and Role of Public Health 
 Although much of the effort for prevention has focused on acute care 
facilities, non-acute care settings also provide care for patients colonized or 
infected with these organisms. Limiting prevention efforts to acute care settings 
fails to take into account the presence of MDROs across different health care 
settings. Broadening the approach to prevention requires employing setting-
specific infection prevention strategies in all health care facilities but also requires 
a method for enhanced communication to ensure that proper infection-control 
practices are continued when patients are transferred between levels of care.26,48  
 
COLISTIN IN THE TREATMENT OF CARBAPENEM RESISTANT 
PSEUDOMONAS AERUGINOSA AND ACINETOBACTER BAUMANNII 
Colistin, a polymyxin antibiotic (polymyxin E), was first discovered in the 
1940s but was not used clinically until the late 1950s. Historically, colistin was 
used to combat infections caused by the gram-negative bacteria. Reports of 
nephrotoxicity and neurotoxicity, however, deterred physicians from using the 
antibiotic, especially with the emergence of other less toxic antibiotics (e.g., 
aminoglycosides). Hence between the 1970s and 1990s, colistin was not used 
often.50 
 
Nowadays, the lack of treatment options for MDR bacteria such as 
Acinetobacter baumannii and Pseudomonas aeruginosa has led to the 
reemergence of colistin as an antimicrobial therapy.  
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Colistin is available in two forms, colistin sulfate and colistimethate 
sodium, administered topically and parenterally, respectively. Both forms can be 
inhaled.  
 
MECHANISM OF ACTION 
Colistin disrupts the outer membrane and releases lipopolysaccharides. 
Change in the permeability of the bacterial membrane leads to leakage of the cell 
content and subsequently cell lysis and death. Colistin also has the ability to bind 
and neutralize the lipopolysaccharide molecule of bacteria, giving it anti-
endotoxin activity.51,52  
 
SPECTRUM OF ACTIVITY 
Colistin has a narrow antibacterial spectrum of activity, predominantly 
against gram-negative isolates. Most significantly, it displays in vitro activity 
against MDR gram-negative pathogens such as A. baumannii, P. aeruginosa, and 
K. pneumoniae. Colistin also has activity against other isolates such as members 
of Enterobacteriaceae - Escherichia coli, Salmonella species, Shigella species, 
Stenotrophomonas maltophilia, Haemophilus influenzae, Bordetella pertussis, and 
Legionella pneumophila. 
 
COLISTIN RESISTANCE  
Although colistin is often considered as a reliable agent to treat 
carbapenem resistant P.aeruginosa and A. baumannii, reports of colistin resistant 
strains are on the rise. Recent studies have shown varying rates of resistance as 
well as the occurrence of hetero-resistant strains. Hetero-resistance occurs when 
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subpopulations within the strain exhibit reduced susceptibility although the 
overall MIC is not altered. This makes detection of resistant subpopulations 
impossible with MIC alone.  
 
According to Mohanty et al, in India, the prevalence of colistin resistance 
was found to be 6% in A.baumannii and about 8% in P.aeruginosa. Taneja et al 
reported the colistin resistance in A.baumannii was about 3.5%.4,53 Baurah FK et 
al in his study in 2014 reported that P.aeruginosa isolates were 100% susceptible 
to colistin.54 
 
MECHANISM OF RESISTANCE 
 Resistance to colistin can develop through adaptive or mutational 
mechanisms. Mechanism of resistance includes changes in the structure of the 
bacterial negatively charged surface lipopolysaccharides and lipid A. These 
modifications occur as a result of the activation of the PmrA-PmrB system, which 
is regulated by the PhoP-PhoQ system.50,51,52  
 
 Colistin resistance is recently due to a plasmid mediated gene mcr-1 in 
Escherichia coli. It was first isolated in China in 2015; this is not yet identified in 
other species. Because of the possibility of the transfer of this gene from one 
bacterial species to other, their global distribution and close monitoring of colistin 
resistance is warranted.55 SENTRY Antimicrobial Surveillance Program is tracing 
the global spread of mcr-1 gene since it was identified. 
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The development of colistin resistance has also been linked to inadequate 
dosing. This highlights the importance of dose optimization, especially in 
critically ill patients with MDR bacterial infections. Although higher doses appear 
beneficial, the lack of pharmacodynamic and pharmacokinetic data regarding 
colistin makes determination of appropriate dosing difficult. Colistin remains an 
essential alternative for most MDR gram-negative infections; however, cases of 
resistant strains should be a cause of great concern. 
 
  
Materials & Methods 
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MATERIALS AND METHODS 
Place of study:  
This study was conducted at Institute of Microbiology, Madras Medical 
College & Rajiv Gandhi Government General Hospital, Chennai-3. 
 
Study period: 
 This study was conducted for one year from April 2016 to March 2017 
 
Study type: 
Descriptive study 
 
Ethical consideration: 
 Approval was obtained from the Institutional Ethics Committee before 
starting the study. Informed written consent was obtained from all the patients 
participated in this study. All patients satisfying the inclusion criteria were 
included. 
 
Statistical analysis: 
 Statistical analyses were carried out using Statistical Packages for Social 
Sciences (SPSS). The proportional data of this cross sectional study were 
analyzed using Pearson’s Chi Square analysis test. 
 
Study population: 
A total of 150 (75 P.aeruginosa and 75 A.baumannii) clinically significant, 
consecutive, non-repetitive isolates of Pseudomonas aeruginosa and 
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Acinetobacter baumannii were included in this study. The isolates were obtained 
from clinical specimens including sputum, endotracheal aspirate, bronchial wash, 
pleural fluid, ascitic fluid, peritoneal dialysis fluid, blood, urine, cerebrospinal 
fluid and wound swab of patients admitted in various wards. 
 
Inclusion Criteria: 
1. Clinically significant, consecutive, non-repetitive isolates of Pseudomonas 
aeruginosa and Acinetobacter baumannii were included. The significance 
of the isolates were based on two or more of the following criteria – 
clinical history, presence of organism in Gram stain, presence of 
intracellular forms of the organism and pure growth in culture with a 
significant colony count wherever applicable. 
2. Patient aged more than 18 years. 
 
Exclusion Criteria: 
1. Isolates of repeated samples from the same patient were not included in the 
study. 
2. Patients with colonization of Pseudomonas aeruginosa and Acinetobacter 
baumannii with no apparent clinical illness. 
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 Preliminary identification of the isolates of Pseudomonas aeruginosa was 
done based on the following characteristics: 
 
1. Colony Morphology: 
On Nutrient agar – Opaque, irregular colonies with metallic sheen and blue 
green diffusible pigment. 
 
On Blood agar – Spreading and flat colonies with serrated edges; with or 
without hemolysis. 
 
On MacConkey Agar – Non-lactose fermenting colonies. 
 
2. The isolates were subjected to preliminary tests like Gram stain, catalase test, 
oxidase test and motility by hanging drop method. 
 
3. The isolates which were gram-negative bacilli, catalase positive, oxidase 
positive and motile were subjected to biochemical reactions for further 
confirmation. 
 
4. The biochemical reactions performed were Hugh – Leifson’s oxidative 
fermentative test, Indole production using Kovac’s reagent, Triple sugar iron 
medium for sugar fermentation and hydrogen sulphide production, citrate 
utilization test, urea hydrolysis test, Moeller’s decarboxylation (arginine 
dihyrolysis). 
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Table 5: Biochemical reactions of Pseudomonas aeruginosa 
OF Glucose test Oxidative 
Indole test Negative 
Triple sugar iron media Alkaline slant/Alkaline butt,  no gas, no H2S 
Citrate test Positive 
Urea hydrolysis Variable 
Growth at 42oC Positive 
Pyocyanin/Pyoverdin Present 
Arginine Dihydrolysed 
Polymyxin B (300U) Sensitive 
  
Preliminary identification of the isolates of Acinetobacter baumannii was done 
based on the following characteristics:  
1. Colony Morphology: 
On Blood agar – Small, circular, convex, smooth colonies with or without 
hemolysis.   
On MacConkey Agar – Non-lactose fermenting colonies sometimes with 
pinkish hue. 
 
2. The isolates were subjected to preliminary tests like Gram stain, catalase test, 
oxidase test and motility by hanging drop method. 
3. The isolates which were gram-negative coccobacilli, catalase positive, oxidase 
negative and non-motile were subjected to biochemical reactions for further 
confirmation. 
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4. The biochemical reactions performed were Hugh – Leifson’s oxidative 
fermentative test, Nitrate reduction test, Indole production using Kovac’s 
reagent, triple sugar iron medium for sugar fermentation and hydrogen 
sulphide production, citrate utilization test, urea hydrolysis test. 
 
Table 6: Biochemical reactions of Acinetobacter baumannii 
 
OF (Glucose) test Oxidative 
Nitrate reduction test Negative 
Indole test Negative 
Triple sugar iron media Alkaline slant/Alkaline butt, no gas, no H2S 
Citrate test Positive 
Urea hydrolysis test Negative 
Growth at 42oC Positive 
10% OF Lactose Fermented 
 
 
ANTIMICROBIAL SENSITIVTY TESTING 
Disc Diffusion Method: 
 Antimicrobial sensitivity testing was performed for all the isolates by 
Kirby-Bauer disc diffusion method on Mueller-Hinton agar plates. 
 
 Three to four colonies were inoculated in peptone water and incubated for 
two hours at 37ºC, to bring the organism to logarithmic phase. The turbidity of the 
suspension was adjusted to 0.5 McFarland standards. Within fifteen minutes of 
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preparation of the suspension, a sterile cotton swab was immersed in the 
suspension and the excess suspension is removed by rotating the swab against the 
wall of the test tube. A lawn culture of the inoculum was made by streaking the 
swab over the surface of the plate in three directions. After about 10 to 15 
minutes, the antibiotic discs were placed, five on each plate and incubated at 37ºC 
for 20 to 24 hours. 
 
 Zone of inhibition of bacterial growth around the antibiotic discs were 
measured using the Himedia scale. Interpretations were made using the Clinical 
and Laboratory Standards Institute, USA guidelines – January 2016, M100S. 
 
Table 7: Panel of Antibiotics for Pseudomonas aeruginosa isolates and 
interpretative criteria 
ANTIBIOTICS 
ZONE OF INHIBITION (mm) 
SENSITIVE INTERMEDIATE RESISTANT 
Ceftazidime (30µg) ≥18 15-17 ≤14 
Piperacillin-Tazobactam 
(100/10 µg) ≥21 15-20 ≤14 
Cefepime (30 µg) ≥18 15-17 ≤14 
Gentamicin (10 µg) ≥15 13-14 ≤12 
Amikacin (30 µg) ≥17 15-16 ≤14 
Ciprofloxacin (5 µg) ≥21 16-20 ≤15 
Meropenem (10 µg) ≥19 16-18 ≤15 
Imipenem (10 µg) ≥19 16-18 ≤15 
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Table 8: Panel of Antibiotics for Acinetobacter baumannii isolates and 
interpretative criteria 
ANTIBIOTICS 
ZONE OF INHIBITION (mm) 
SENSITIVE INTERMEDIATE RESISTANT 
Ceftazidime (30µg) ≥18 15-17 ≤14 
Piperacillin-Tazobactam 
(100/10 µg) ≥21 18-20 ≤17 
Tetracycline (30 µg) ≥15 12-14 ≤11 
Trimethoprim/Sulfamethoxazole 
(1.25/23.75 µg) ≥16 11-15 ≤10 
Gentamicin (10 µg) ≥15 13-14 ≤12 
Amikacin (30 µg) ≥17 15-16 ≤14 
Ciprofloxacin (5 µg) ≥21 16-20 ≤15 
Meropenem (10 µg) ≥18 15-17 ≤14 
Imipenem (10 µg) ≥22 19-21 ≤18 
 
MINIMUM INHIBITORY CONCENTRATION (MIC) OF IMIPENEM  
 MIC of Imipenem was determined by Epsilometer test (E-test) for all the 
imipenem intermediate and resistant isolates of Pseudomonas aeruginosa and 
Acinetobacter baumannii. 
 
 A predefined stable imipenem (Biomerieux) non-porous plastic E-strip of 
5mm width and 60mm length (with concentration gradient ranges from 0.02 to 
32µg/ml) is applied on to 0.5 McFarland standard suspension inoculated Mueller-
Hinton agar plate, incubated at 37ºC for 20-24 hours. After incubation whereby 
bacterial growth becomes visible, a symmetrical inhibition ellipse centered along 
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the strip is formed. The MIC value is read from the scale in terms of µg/ml where 
the point of ellipse intersects the strip. 
 
 The same MIC interpretative criteria recommended in CLSI guidelines 
2016 for broth dilution method were applied for E-test method.  
 
Table 9: MIC interpretative criteria for Imipenem 
Organism 
Minimum Inhibitory Concentration (MIC) - 
µg/ml 
Sensitive Intermediate Resistant 
Pseudomonas aeruginosa ≤2 4 ≥8 
Acinetobacter baumannii ≤2 4 ≥8 
 
 According to CDC-NHSN, isolates showing resistance to at least one agent 
in three or four groups of antibiotics (cephalosporins, carbapenems, 
fluoroquinolones and aminoglycosides) were considered as Multi-Drug Resistant 
(MDR) in this study. 
 
DETECTION OF ANTIMICROBIAL RESISTANCE 
Phenotypic screening methods 
 All the isolates included in this study were subjected to Extended Spectrum 
Beta-lactamase (ESBL) screening test using ceftazidime (30µg) and/or cefepime 
(30µg), AmpC beta-lactamase screening test using cefoxitin (30µg) and 
carbapenemase screening test using imipenem (10µg) and meropenem (10µg) 
discs. The isolates which were positive in the screening test were subjected to 
respective confirmatory tests using appropriate antibiotic discs.  
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Phenotypic confirmatory test for ESBL production- Combined disc 
method3,56 
 In this method, a lawn culture of the test isolates was made as for disc 
diffusion method. Ceftazidime (30µg) and ceftazidime-clavulanic acid 
(30µg/10µg) discs- Himedia, were placed at a distance of 20mm centre to centre 
on the Mueller-Hinton agar plate, incubated at 37ºC for 20-24 hours. The test 
isolate was considered to produce ESBL if the zone of inhibition around the 
ceftazidime-clavulanic acid disc was ≥5mm that the zone around ceftazidime disc 
alone.  
 
Phenotypic test for AmpC detection3,57 
 The isolates which were resistant to cefoxitin [(30µg) <18mm] were 
considered as AmpC screening test positive. AmpC production was confirmed by 
placing cefoxitin (30µg) and cefoxitin-phenylboronic acid (30/400µg) at a 
distance of 20mm on the Muller-Hinton agar plate. The test isolate that 
demonstrated a zone of inhibition of ≥5mm around cefoxitin-inhibitor than that 
around the cefoxitin alone was considered as AmpC producer. 
 
Carbapenemase detection by Modified Hodge Test (MHT)58,59 
 Isolates positive for screening test in the disc diffusion (resistant to 
carbapenems) was further processed by modified Hodge test to detect 
carbapenemase production. 
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 0.5 McFarland standard suspension of E.coli ATCC 25922 was prepared in 
nutrient broth or saline and diluted 1:10 in saline or broth. A lawn culture of 1:10 
dilution E.coli ATCC 25922 was done on to a Mueller Hinton Agar plate and 
allowed to dry for 3-5 minutes. A 10µg meropenem disc is placed in the center of 
the test area. In a straight line, the test organism was streaked from the edge of the 
disc to the edge of the plate and incubated at 370C for 16-20 hours. 
 
Interpretation 
Enhanced growth (Clover-leaf indentation) = Positive 
No enhanced growth = Negative 
 
Metallo beta-lactamase (MBL) detection by combined disc method 
 Metallo-β-Lactamase production for the carbapenem resistant isolates was 
screened by imipenem (10µg) –EDTA (750µg), meropenem (10µg) – EDTA 
(930µg) and ceftazidime (30µg) –EDTA (930µg) combined disc method. An 
increase in zone size of ≥ 7 mm around Inhibitor combination disc compared to 
disc without inhibitor was considered as MBL positive.36 
 
COLISTIN SUCEPTIBILITY FOR THE CARBAPENEM RESISTANT 
ISOLATES 
 Colistin MIC was determined for carbapenem resistant isolates by 
Epsilometer test (E-test) using colistin E-strips of concentration gradient (0.016 to 
256µg/ml (Biomerieux). 
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Table 10: MIC interpretive criteria for Colistin according to CLSI 
guidelines, 2016 
Organism 
Minimum Inhibitory Concentration (MIC) - µg/ml 
Sensitive Intermediate Resistant 
Pseudomonas 
aeruginosa ≤2 - ≥4 
Acinetobacter 
baumannii ≤2 - ≥4 
 
MOLECULAR CHARACTERIZATION  
 The Carbapenem resistant Pseudomonas aeruginosa isolates which were 
positive for MBL production and carbapenem resistant Acinetobacter baumannii 
isolates which were positive for carbapenemase production by modified Hodge 
test were subjected to conventional Polymerase Chain Reaction (PCR) for the 
detection blaVIM/blaNDM-1 and blaOXA-23 genes respectively. 
 
Bacterial DNA Purification 
1. 1ml of overnight broth culture was centrifuged at 6000rpm for 5min. 
Supernatant was discarded and pellet was suspended in 0.2ml PBS. 
2. 180μl of Lysozyme digestion buffer and 20μl of Lysozyme [10mg/ml] 
were added to the pellet and incubated at 37ºC for 15min. 
3. 400μl of Binding buffer, 5μl of internal control template and 20μl of 
Proteinase K were added and mixed well by inverting several times; 
incubated at 56ºC for 15min. 300μl of Ethanol was added and mixed well. 
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4. The entire mixture is transferred into the PureFast® spin column and 
centrifuged for 1 min. Flow-through was discarded and the column is 
placed back into the same collection tube. 
5. 500μl Wash buffer-1 was added to the PureFast® spin column and 
centrifuged for 30-60 seconds and the column is placed back into the same 
collection tube after discarding the flow through. 
6. Then 500μl Wash buffer-2 was added to the PureFast® spin column and 
centrifuged for 30-60 seconds and the column is placed back into the same 
collection tube after discarding the flow through; centrifuge for additional 
1 min.This step is essential to avoid residual ethanol. 
7. The PureFast® spin column was transferred into a fresh 1.5 ml micro-
centrifuge tube. Then, 100μl of Elution Buffer was added to the center of 
PureFast® spin column membrane; incubated for 1 min at room 
temperature and centrifuged for 2 min. 
8. The column was discarded and the purified DNA was stored at -20°C. 
Quality of extracted DNA was checked by loading in 1% agarose gel and 
5μl of extracted DNA was used for PCR amplification. 
 
PCR Procedure: 
 PCR was done at HELINI BIOMOLECULES, Neelankarai, Chennai 
 
1. Reactions set up as follows: 
Components Quantity 
HELINI RedDye PCR Master Mix 10μl 
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HELINI Ready to use – OXA23 gene Primer Mix / VIM gene primer mix/ 
NDM-1 gene primer mix 5μl 
Purified Bacterial DNA 5μl 
Total volume 20μl 
 
2. Reaction components were mixed gently; placed into PCR machine and 
programmed as  
Initial Denaturation: 94ºC for 5 min 
Denaturation: 94ºC for 30sec 
Annealing: 58ºC for 30sec   35 cycles 
Extension: 72ºC for 30sec 
Final extension: 72º C for 5 min 
 
Loading 
 2% agarose gel was prepared. [2gm of agarose in 100ml of 1X TAE 
buffer]; electrophoresis was done at 50V till the dye reaches three fourth distances 
and the bands were observed in UV Transilluminator. 
 
Agarose gel electrophoresis 
1. 2% agarose gel was prepared. (2gm agarose was mixed in 100ml of 1X 
TAE buffer and melted using microoven). When the agarose gel 
temperature was around 60ºC, 5μl of Ethidium bromide was added. Warm 
agarose solution was poured slowly into the gel platform and the gel was 
kept undisturbed till the agarose solidifies. 
2. 1XTAE buffer was poured into submarine gel tank and the gel is placed. 
55 
 
 
3. PCR Samples were loaded after mixed with gel loading dye along with 
10μl HELINI 100bp DNA Ladder. [100bp, 200bp, 300bp, 400bp, 500bp, 
600bp, 700bp, 800bp, 900bp,1000bp and 1500bp] 
4. Electrophoresis was done at 50V till the dye reaches three fourth distances 
and the bands were observed in UV Transilluminator. 
5. PCR products were confirmed by the band formation of corresponding 
product size. 
 Product size for blaOXA-23 – 453 bp 
 Product size for blaVIM – 480 bp 
 Product size for blaNDM-1 – 475 bp 
  
Results 
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RESULTS 
 
 In this descriptive study, 75 clinically significant, consecutive, non-
repetitive Pseudomonas aeruginosa and 75 Acinetobacter baumannii isolates 
collected from various clinical specimens during April 2016 to March 2017 were 
included. 
 
Table 11: Distribution of Pseudomonas aeruginosa isolates among various 
clinical samples (n=75) 
Clinical Samples No.of isolates (%) 
Pus 32 (42.7%) 
Urine 13 (17.3%) 
Respiratory specimens (endotracheal aspirate, 
sputum, bronchial wash) 25 (33.3%) 
Fluids (Peritoneal dialysis fluid, pleural fluid) 3 (4%) 
Devices (catheter tip) 2 (2.7%) 
 
The vast majority of Pseudomonas aeruginosa were isolated from pus 
samples. These samples were predominantly from patients with surgical site 
infections and diabetic foot infection. 
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Table 12: Distribution of Acinetobacter baumannii isolates among various 
clinical samples (n=75) 
 
Clinical Samples No .of isolates (%) 
Pus 21 (28%) 
Urine 18 (24%) 
Respiratory specimens (endotracheal aspirate, 
sputum) 22 (29.3 %) 
Blood 6 (8%) 
Fluids (Peritoneal dialysis fluid, ascitic fluid) 7 (9.3%) 
Devices (Catheter tip) 1 (1.3%) 
 
Most of the Acinetobacter baumannii were isolated from respiratory 
specimens (29.3%; endotracheal aspirate and sputum) followed by pus (28%). 
 
Fig:4 Sample wise distribution of P.aeruginosa and A.baumannii 
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Table 13: Distribution of Pseudomonas aeruginosa isolates among various 
Clinical settings (n=75) 
Clinical Specialty No. of isolates (%) 
ICU 7 (9.3%) 
Surgical wards 28 (37.3%) 
Medicine wards 16 (21.3%) 
Renal Unit 12 (16%) 
Orthopedics 12 (16%) 
  
 P.aeruginosa was isolated more commonly from the surgical wards which 
included general surgery, neurosurgery, vascular surgery, ENT ward and 
cardiothoracic surgery. 
 
Fig 5: Distribution of P.aeruginosa among various clinical settings 
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Table 14: Distribution of Acinetobacter baumannii isolates among various 
clinical settings (n=75) 
Clinical Specialty No. of isolates (%) 
ICU 13 (17.3%) 
Surgical wards 22 (29.3%) 
Medical wards 19 (25.3%) 
Renal unit 15 (20%) 
Orthopedics 6 (8%) 
 
Fig 6: Distribution of A.baumannii isolates among various clinical settings 
 
 
 
 A.baumannii isolates were predominantly isolated from surgical wards 
(29.3%) which included general surgery, vascular surgery, neurosurgery and 
cardiothoracic surgery. 
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Table 15: Antimicrobial Susceptibility pattern of Pseudomonas aeruginosa 
isolates (n=75) 
 
Antimicrobial agent No. of susceptible isolates (%) 
No. of resistant 
isolates (%) 
Ceftazidime (30 µg) 26 (34.7%) 49 (65.3%) 
Piperacillin-Tazobactam 
(100/10µg) 52 (69.3%) 23 (30.7%) 
Gentamicin (10 µg) 48 (64%) 27 (36%) 
Cefepime (30 µg) 42 (56%) 33 (44%) 
Amikacin (30 µg) 63 (84%) 12 (16%) 
Ciprofloxacin (5 µg) 45 (60%) 30 (40%) 
Meropenem (10 µg) 66 (88%) 9 (12%) 
Imipenem (10 µg) 71 (94.7%) 4 (5.3%) 
 
 Higher susceptibility was seen with meropenem (88%) followed by 
amikacin (84%). Nine out of 75 isolates (12%) were resistant to meropenem 
whereas only four isolates were resistant to Imipenem (5.3%); these belong to 
MRIS (Meropenem Resistant Imipenem Sensitive) phenotype. 
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Table 16: Antimicrobial Susceptibility pattern of Acinetobacter baumannii 
isolates (n=75) 
 
Antimicrobial agent No. of susceptible isolates (%) 
No. of resistant 
isolates (%) 
Ceftazidime (30 µg) 14 (18.7%) 61 (81.3%) 
Ciprofloxacin (5 µg) 35 (46.7%) 40 (53.3%) 
Gentamicin (10 µg) 22 (29.3%) 53 (70.1%) 
Meropenem (10 µg) 65 (86.7%) 10 (13.3%) 
Imipenem (10 µg) 65 (86.7%) 10 (13.3%) 
Piperacillin-Tazobactam 
(100/10µg) 48 (64%) 27 (36%) 
Amikacin (30 µg) 51 (68%) 24 (32%) 
Trimethoprim-sulfamethoxazole 
(1.25/23.75µg) 14 (18.7%) 61 (81.3%) 
Tetracycline (30 µg) 42 (56%) 33 (44%) 
 
 A.baumannii isolates were highly susceptible to meropenem and imipenem 
(86.7%) whereas they are least susceptible to ceftazidime and trimethoprim-
sulfamethoxazole (18.7%). 
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Table 17: Distribution of Multidrug Resistance and Carbapenem resistance 
among P.aeruginosa and A.baumannii isolates 
 
Organism 
No. of isolates 
Total isolates (n) MDR (%) Carbapenem resistant (%) 
Pseudomonas 
aeruginosa 75 22 (29.3%) 9 (12%) 
Acinetobacter 
baumannii 75 38 (50.7%) 10 (13%) 
 
MDR – Multidrug resistant  
 
 Among 75 P.aeruginosa isolates, about 29.3% and 12% were multidrug 
resistant and carbapenem resistant, respectively; among A.baumannii isolates, 
50.7% were multidrug resistant whereas 13% were Carbapenem Resistant 
A.baumannii (CRAB). 
 
Table 18: Distribution of Multidrug Resistant P.aeruginosa and A.baumannii 
isolates among various samples 
Clinical samples 
No. of MDR 
P.aeruginosa isolates 
(n=22) 
No. of MDR 
A.baumannii isolates 
(n=38) 
Urine 6 (27.3%) 8 (21.1%) 
Respiratory specimens 9 (40.9%) 12 (31.6%) 
Pus 6 (27.3%) 12 (31.6%) 
Fluids 1 (4.5%) 1 (2.6%) 
Blood - 5 (13.2%) 
 
MDR – Multidrug resistant 
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Fig: 7 Sample wise distribution of MDR isolates 
 
 
 
MDR P.aeruginosa isolates were predominantly from respiratory 
specimens (which included endotracheal aspirate - 22.7%, sputum – 13.6%, 
bronchial wash – 4.5%) whereas multidrug resistant A.baumannii isolates were 
equally distributed between respiratory specimens (which included endotracheal 
aspirate and sputum) and pus samples (31.6)%. 
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Table 19: Phenotypic characterization of resistance among Pseudomonas 
aeruginosa isolates (n=75) 
Phenotypic tests No. of isolates positive (%) 
ESBL detection 17 (22.7%) 
AmpC detection 11 (14.7%) 
ESBL & AmpC - 
Carbapenem resistant (by disc diffusion) 9 (12%) 
Carbapenemase production by Modified Hodge 
test 4 (5.3%) 
MBL detection 4(5.3%) 
AmpC & MBL - 
 
 From this table, ESBL was the most common resistance mechanism 
against β-lactams for P.aeruginosa. Among the carbapenem resistant isolates 
(n=9), only four isolates were resistant to both imipenem and meropenem; these 
belong to IRMR phenotype which is predominantly enzyme (metallo-β-
lactamase) mediated; other five isolates were MRIS phenotype which is mainly 
due to efflux pump. Therefore, the carbapenem resistance in P.aeruginosa is 
predominantly non-enzyme mediated. 
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Table 20: Phenotypic characterization of resistance among Acinetobacter 
baumannii isolates (n=75) 
Phenotypic tests No. of isolates positive (%) 
ESBL detection 27 (36%) 
AmpC detection 19 (25.3%) 
ESBL & AmpC 2 (2.7%) 
Carbapenem resistant (by disc diffusion) 10 (13.3%) 
Carbapenemase production by Modified Hodge 
test 9 (12%) 
MBL detection 3 (4%) 
AmpC & MBL 1 (1.3%) 
Carbapenemase & AmpC co-production 2 (2.7%) 
 
 Among A.baumannii, ESBL was the predominant resistance mechanism 
against β-lactams. All the 10 carbapenem resistant isolates were resistant to both 
imipenem and meropenem which belong to IRMR phenotype (enzyme mediated); 
only three of them were found to be MBL producers. This indicates that 
carbapenem hydrolyzing enzyme production was the predominant resistance 
mechanism against carbapenem in A.baumannii. 
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Table 21: Distribution of Carbapenem resistant P.aeruginosa and 
A.baumannii isolates among various samples 
Clinical samples 
No. of Carbapenem 
resistant P.aeruginosa 
(n=9) 
No. of Carbapenem 
resistant A.baumannii 
(n=10) 
Respiratory 
specimens 4 (44.4%) 6 (60%) 
Urine 4 (44.4%) 1 (10%) 
Blood - 3 (30%) 
Fluids 1 (11.1%) - 
*p value 0.006 0.007 
 
*p < 0.05 – Statistically significant 
 
Fig 8: Distribution of Carbapenem resistant P.aeruginosa and A.baumannii 
isolates among clinical samples 
 
Carbapenem resistant P.aeruginosa and A.baumannii were predominantly 
isolated from respiratory specimens (especially from endotracheal aspirate). This 
association was found to be statistically significant. 
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Table 22: Distribution of Carbapenem resistant isolates among various 
Clinical settings (n=19) 
Clinical Wards 
No. of carbapenem 
resistant 
P.aeruginosa (n=9) 
No. of carbapenem 
resistant A.baumannii 
(n=10) 
Total 
(n=19) 
ICU 3 7 10 (52.6%) 
Orthopaedic 
ward 3 - 3 (15.8%) 
Surgical wards 2 1 3 (15.8%) 
Medicine wards - 2 2 (10.5%) 
Renal Unit 1 - 1 (5.3%) 
*p value 0.047 0.001 19 
 
*p < 0.05 – significant 
 
Fig: 9 Distribution of Carbapenem resistant isolates 
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 Majority of the carbapenem resistant P.aeruginosa and A.baumannii 
isolates were found to be from Intensive care unit (52.6%) which is statistically 
significant (p <0.05). 
 
Table 23: Minimum Inhibitory Concentration of Imipenem for the Imipenem 
resistant isolates by disc diffusion method (n=14) 
Organism 
No. of isolates with Minimum Inhibitory Concentration  
(MIC) - µg/ml 
≤2 Sensitive 4-8 Intermediate ≥8 Resistant 
P.aeruginosa (n=4) - 1 3 
A.baumannii (n=10) - 2 8 
 
 Among the 14 Imipenem resistant isolates, three isolates (one P.aeruginosa 
and two A.baumannii isolates) were with MIC in the intermediate range. 
 
Table 24: Risk factors associated with carbapenem resistance (n=19) 
Risk factors Occurrence (%) 
Hospital stay > 7 days 14 (73.7%) 
Mechanical Ventilation 12 (63.2%) 
ICU admission 10 (52.6%) 
Urinary catheterization 18 (94.7%) 
Previous use of antibiotic (Carbapenem) 5 (26.3%) 
Previous surgery 3 (15.8%) 
 
*Mortality – 6 (31.2%) 
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 Carbapenem resistance rate was high in the ICU due to these risk factors 
such as prolonged hospital stay, interventions (mechanical ventilation, 
catheterization) and previous use of antibiotic especially carbapenems. 
 
Table 25: Antimicrobial resistance pattern among Carbapenem susceptible 
and Carbapenem resistant P.aeruginosa isolates 
Antibiotic 
No. (%) of resistant isolates among 
Total 
(n=75) 
Carbapenem 
susceptible 
isolates (n=66) 
Carbapenem 
resistant 
isolates (n=9) 
*p value 
Ceftazidime 
(30µg) 49 (65.3%) 40 (60.6%) 9 (100%) 0.023 
Cefepime  
(30 µg) 33 (44%) 24 (36.4%) 9 (100%) 0.0001 
Piperacillin- 
Tazobactam 
(100/10µg) 
23 (30.7%) 14 (21.2%) 9 (100%) 0.0001 
Amikacin  
(30 µg) 12 (16%) 8 (12.1%) 4 (44.4%) 0.032 
Gentamicin 
(10µg) 27 (36%) 19 (28.8%) 8 (88.8%) 0.001 
Ciprofloxacin 
(5µg) 30 (40%) 22 (33.3%) 8 (88.8%) 0.002 
 
*p < 0.05 – Statistically significant 
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Table 26: Antimicrobial resistance pattern among Carbapenem susceptible 
and Carbapenem resistant A.baumannii isolates 
Antibiotic 
No. (%) of resistant isolates among 
Total 
(n=75) 
Carbapenem 
susceptible 
isolates (n=65) 
Carbapenem 
resistant 
isolates (n=10) 
*p value 
Ceftazidime 
(30µg) 61 (81.3%) 51 (78.5%) 10 (100%) 0.109 
Piperacillin-
Tazobactam 
(100/10µg) 
27 (36%) 17 (26.2%) 10 (100%) 0.0001 
Amikacin (30 µg) 24 (32%) 16 (24.6%) 8 (80%) 0.001 
Gentamicin 
(10µg) 53 (70.1%) 43 (66.2%) 10 (100%) 0.024 
Ciprofloxacin 
(5µg) 40 (53.3%) 32 (49.2%) 8 (80% 0.068 
Trimethoprim-
Sulfamethoxazole 
(1.25/23.75 µg) 
61 (81.3%) 51 (78.5%) 10 (100%) 0.109 
Tetracycline 
(30µg) 33 (44%) 25 (38.5%) 8 (80%) 0.09 
 
*p< 0.05 – Statistically significant 
 
 Isolates which were found to be carbapenem resistant were also resistant to 
many of the other antibiotics and this was statistically significant. 
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Table 27: Molecular characterization of MBL positive  
P.aeruginosa isolates (n=4) 
 
MBL positive 
P.aeruginosa (n=4) 
blaVIM positive blaNDM-1 positive 
blaVIM & 
blaNDM-1 
negative 
1 2 1 
 
 Genotypic characterization among the four MBL producing P.aeruginosa, 
two were found to be blaNDM-1 positive and one blaVIM positive.  
 
Table 28: Molecular characterization of MHT positive A.baumannii isolates 
(n=9) 
Carbapenemase 
producing (MHT 
positive) A.baumannii 
(n=9) 
blaOXA-23 positive blaOXA-23 negative 
4 5 
 
 Genotypic characterization among the nine carbapenemase producing 
A.baumannii, four were found to be blaOXA-23 positive. 
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Table 29: MIC of Colistin for the Carbapenem resistant isolates (n=19) 
 
Organism 
No. of isolates with Minimum Inhibitory Concentration      
(MIC) - µg/ml 
Sensitive Resistant 
≤ 0.5 0.5 – 1 1 – 2 ≥ 4 
P.aeruginosa 
(n=9) 2 4 3 - 
A.baumannii 
(n=10) 5 4 1 - 
 
 All the carbapenem resistant P.aeruginosa and A.baumannii were 
susceptible to colistin by E-test. Four isolates (three strains of P.aeruginosa and 
one strain of A.baumannii) were having MIC in the upper limit of susceptible 
range (1.5 to 2 µg/ml). 
 
  
Discussion 
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DISCUSSION 
 
 Currently, antimicrobial resistance especially for carbapenem is a major 
public health issue which increases morbidity and mortality in hospitalized 
patients. Among the various mechanisms for carbapenem resistance, 
carbapenemase production is plasmid mediated; these resistance genes on 
plasmids can be transferred horizontally from one bacterium to another bacterial 
species. This is the major cause of dissemination of antimicrobial resistance genes 
between various bacterial species. Therefore, identifying the prevalence and 
mechanism of carbapenem resistance and their susceptibility to other antibiotics 
are necessary to formulate antibiotic policies in a hospital set–up and to determine 
various treatment options.  
 
 In this study, the majority of Pseudomonas aeruginosa isolates were from 
pus sample (42.7%), followed by respiratory specimens (33.3%). Similarly, 
Acinetobacter baumannii isolates were predominantly isolated from respiratory 
specimens (29.3%) followed by pus sample (28%) – Table 11&12. In a study 
conducted by Shasikala et al at Pondicherry, 27.6% of the P.aeruginosa isolates 
were from wound infections. Padmalakshmi et al reported 37.5% of A.baumannii 
isolates were from respiratory specimen which is similar to this study. 7,60  Both 
P.aeruginosa and A.baumannii are ubiquitous, can tolerate harsh environments 
and hence, colonizes the skin and respiratory tract more commonly in hospitalized 
patients.  
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 Regarding specialty wise distribution, P.aeruginosa was predominantly 
isolated from surgical units (37.3%) mainly from post operative infections and 
patients with diabetic foot; followed by medical wards (21.3%); similarly, 
A.baumannii was isolated mostly from surgical wards (29.3%),  followed by 
medicine wards (25.3%) – Table 13&14. 
 
 The overall resistance of P.aeruginosa vs A.baumannii to the antibiotics 
tested was ceftazidime (65.3% vs 81.3%), pipercillin-tazobactam (30.7% vs 36%), 
amikacin (16% vs 32%), gentamicin (36% vs 70.1%), ciprofloxacin (40% vs 
53.3%), meropenem (12% vs 13.3%) and imipenem (5.3% vs 13.3%) – Table 
15&16. 
 
 This  correlates with a study from United States, in which among 
Acinetobacter species carbapenem resistance rates have been reported from 34% 
to as high as 62.6% and  National Healthcare Safety Network (NHSN) in the 
United States have reported an increase from 33% carbapenem resistance in 2006 
to 2007 to >60% among Acinetobacter species isolates in 2009 to 2010.61,62,63 
According to the study by Hong D J et al, carbapenem resistance rates among 
Pseudomonas aeruginosa isolates in most countries range from 10% to 50% and 
have been reported as low as 3.3% in Canada to >50% in Russia, Southwest Asia, 
and South America.64  
 
 Mohanty et al in their study at New Delhi found that the overall resistance 
of the isolates (P. aeruginosa vs Acinetobacter spp.) to the antibiotics was 
ceftazidime (57.9% vs 84.0%), piperacillin/tazobactam (22.1% vs 42.0%), 
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amikacin (33.7% vs 72.0%), gentamicin (40.0% vs 80.0%), ciprofloxacin (35.8% 
vs 64.0%), meropenem (36.8% vs 62.0%) and imipenem (37.9% vs 64.0%).4 
Benacchinmardi et al in a recent study at PGIMSR, Bengaluru showed 80% of 
P.aeruginosa and about 41% A.baumannii were sensitive to imipenem.65 
According to the study conducted at Trichy in 2015, 8.7% of NFGNB were 
resistant to meropenem.66 This is concordant with the present study which shows 
about 12% carbapenem resistance in P.aeruginosa and 13.3% in A.baumannii. 
These differences in the antimicrobial susceptibility could be due to the 
geographical variation. Therefore, various international authorities emphasize that 
every hospital should have its own antibiotic policy. 
 
 In this study, the prevalence of MDR among P.aeruginosa was found to be 
29.3% and among A.baumannii was 50.7% (Table 17). This is similar to the study 
conducted in Italy by Franesco De et al who showed the prevalence of MDR 
among P.aeruginosa and A.baumannii as 20% and 54% respectively.67 Khan F et 
al reported 30% of P.aeruginosa isolates as MDR68, while Lakshmi et al found 
77% of A.baumannii to be multidrug resistant.69  
 
 Sample wise MDR P.aeruginosa was isolated predominantly from 
respiratory tract specimens (endotracheal aspirate, sputum and bronchial wash) 
accounting for 40.9%; MDR A.baumannii was equally distributed between 
respiratory tract specimens and pus (31.6%) – Table 18. This is in correlation with 
most of the studies67, 68, 69where MDR P.aeruginosa and A.baumannii were 
predominantly isolated from specimens of the respiratory tract.  
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 Among P.aeruginosa, 22.7% strains were phenotypically characterized as 
ESBL producers, 14.7% were AmpC producers, 5.3% were positive for 
carbapenemase production by Modified Hodge test and all these were found to be 
Metalloβ-lactamase by Imipenem-EDTA combined disc method; while among 
A.baumannii 36% strains were ESBL producers, 25.3% were AmpC producers, 
2.7% were Co-producers of ESBL and AmpC, 12% were positive for 
carbapenemase production by Modified Hodge test, 4% were metalloβ-lactamase 
producers and 4% were co-producers of carbapenemase and AmpC (Table 
19&20) .  
 
 According to the study of Gupta et al, among non-fermenters 21.4% were 
ESBL producers, 51.1% were AmpC producers and 21.4% were metallobeta-
lactamase producers.70 Since in this study sample size is low and being a single 
centered study, the true prevalence of resistance mechanisms could not be 
completely evaluated. Multi-centered study with large sample size is required to 
find the overall prevalence of resistance mechanisms in the community.  
 
 Five of the nine meropenem resistant P.aeruginosa isolates were sensitive 
to Imipenem; they were categorized as MRIS (Meropenem Resistant Imipenem 
Sensitive). In MRIS phenotype, the carbapenem resistance could be due to over 
expression of efflux pump which can be confirmed by the genotypic methods. In 
A.baumannii, all the carbapenem resistant isolates were resistant to both 
meropenem and imipenem; they belong to IRMR (Imipenem Resistant 
Meropenem Resistant) phenotype in which the carbapenem resistance is 
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predominantly enzyme mediated (carbapenem hydrolyzing enzymes such as OXA 
type carbapenemases and Ambler class B metalloβlactamases).71 
 
 The emergence of these phenotypes occurs mainly due to the antibiotic 
selection pressures promoted by inappropriate dosage and duration of the 
carbapenems. Hence, it is advisable to perform antimicrobial susceptibility testing 
for each of the carbapenems namely imipenem, meropenem and doripenem, rather 
than testing single carbapenem and to extrapolate the results for other 
carbapenems. 
 
 In P.aeruginosa, carbapenem resistant isolates were equally distributed 
between respiratory specimen especially endotracheal aspirate and urine (44.4%) 
whereas in A.baumannii, carbapenem resistance was noted predominantly among 
respiratory specimen (endotracheal aspirate - 50% & sputum 10%) as most of 
these isolates were from ICU patients on mechanical ventilation (Table 21&22). 
 
 Of the total 19 carbapenem resistant isolates (nine P.aeruginosa and ten 
A.baumannii), 52.6% were isolated from patients admitted in Intensive care units. 
This correlates with the studies conducted in Iran and New Delhi which reported 
53.6% and 67.5% carbapenem resistance among patients admitted in intensive 
care unit respectively.72, 73 This high carbapenem resistance rate in ICU is due to 
the associated risk factors such as prolonged hospital stay, interventions such as 
mechanical ventilation and previous use of antibiotics especially carbapenem.  
 
78 
 
 
 This increase in carbapenem resistance in ICU is alarming and hence it is 
necessary to take various preventive measures which include screening for 
carbapenem resistance carriers in high risk units (surveillance cultures), 
undertaking strict contact precautions for carriers and antibiotic stewardship 
programs to spare carbapenems.  
 
 Among the 14 imipenem resistant isolates (four P.aeruginosa and ten 
A.baumannii), three isolates showed MIC of imipenem in the intermediate range 
(Table 23). Recent studies showed that extended infusion therapy of carbapenem 
for about 30 minutes to 3 hours was found to be effective if the MIC of 
carbapenem falls in the intermediate range (4µg/ml to <8µg/ml).26, 46, 47 Hence, 
mere screening for carbapenem susceptibility is insufficient and detection of MIC 
is essential as it can determine the appropriate treatment regimens. 
 
 Carbapenem resistant P.aeruginosa isolates were also 100% resistant to 
ceftazidime, cefepime and piperacillin-tazobactam; however they were highly 
sensitive to amikacin (55.6%). Similarly, carbapenem resistant A.baumannii 
isolates were 100% resistant to ceftazidime, piperacillin-tazobactam, gentamicin 
and trimethoprim-sulfamethoxazole (Table 25&26). This is statistically significant 
(p<0.05) and in parallel to the study by Mohanty et al, which showed carbapenem 
resistant P.aeruginosa and A.baumannii  were significantly  (p< 0.05) resistant to 
other antibiotics.4  
 
 Since carbapenem resistance is predominantly mediated by multi-drug 
resistance transferrable plasmids, carbapenem resistant strains remain resistant to 
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several other antibiotics including fluoroquinolones, aminoglycosides, third 
generation cephalosporins such as ceftazidime and β-lactam/β-lactamase inhibitor 
combinations. This poses serious problems in choosing the right antibiotic for the 
treatment of hospitalized patients admitted in ICU. This can be controlled by 
various strategies such as strict infection control measures, judicious use of 
antibiotics, antibiotic resistance surveillance programs and antibiotic cycling. 
 
 Out of four MBL producing P.aeruginosa, two isolates were positive for 
blaNDM-1 gene by conventional PCR, one isolate was positive for blaVIM gene and 
one was negative for both; five carbapenem resistant P.aeruginosa isolates were 
MRIS phenotypes which could be due to over expression of efflux pumps. Of the 
nine carbapenemase producing A.baumannii, four were positive for blaOXA-23 gene 
and three were found to be metalloβ-lactamase producers by phenotypic method 
(Table 27&28). Therefore the predominant mechanism for carbapenem resistance 
among P.aeruginosa and A.baumannii was efflux pump over expression and 
carbapenemase production respectively. 
 
 This correlates well with the study by Gniadek T J et al which states that 
“Currently, in the United States and Europe, OXA type carbapenemase production 
(predominantly OXA-23) is the primary resistance mechanism among A. 
baumannii, while the loss of OprD porin expression, without the expression of a 
carbapenemase, is the primary mechanism of resistance among P.aeruginosa”.58,74 
In a study at Christian Medical College, Vellore, IRMS (due to loss of outer 
membrane protein) and MRIS phenotypes of P. aeruginosa were more commonly 
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observed rather than IRMR phenotype which is due to the plasmid mediated 
carbapenemases.71 
 
 All the 19 carbapenem resistant isolates were 100% susceptible to colistin. 
Baurah FK et al in a study in 2014 reported that P.aeruginosa was 100% 
susceptible to Colistin.54 However according to Mohanty et al, in India, the 
prevalence of colistin resistance was found to be 6% in A.baumannii and about 
8% in P.aeruginosa which is in contrast to this study. Taneja et al also reported 
about 3.5 % of A.baumannii to be colistin resistant.4, 53 This variation in the 
prevalence of colistin resistance could be due to the geographic variation and 
different antibiotic policies among various hospitals. 
 
 Four of the 19 carbapenem resistant isolates were having MIC in the upper 
limit of susceptible range (1.5 to 2 µg/ml) – Table 29; this indicates that the MIC 
testing for colistin should be made mandatory before administration to prevent the 
emergence of colistin resistance in a community, as colistin is the only available 
effective antibiotic for the treatment of carbapenem resistant infections.  
 
 Despite the risk of nephrotoxicity in patients receiving colistin, colistin 
may be useful for salvage therapy of carbapenem resistant P. aeruginosa and 
A.baumannii infections where the therapeutic choices are severely limited. 
 
  
Limitations of the study 
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LIMITATIONS OF THE STUDY 
 
Since this is a single centered study with low sample size, the true 
prevalence of resistance mechanisms could not be evaluated. Multi-centered 
studies with larger sample size are required to identify the overall prevalence of 
resistance mechanisms in the community. 
 
Molecular characterization for the carbapenem resistant isolates was done 
only for the most prevalent genes (blaNDM-1, blaVIMand blaOXA-23). There are 
various other genes responsible for carbapenem resistance, which were not 
included in this study. 
  
Summary 
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SUMMARY 
 
 The prevalence of antibiotic susceptibility and resistance mechanisms of 75 
Pseudomonas aeruginosa and 75 Acinetobacter baumannii isolates from 
various clinical specimens were studied. 
 This study shows 29.3% of P.aeruginosa and 50.7% A.baumannii as MDR; 
of this 12% of P.aeruginosa and 13.3% of A.baumannii were carbapenem 
resistant. 
 The carbapenem resistant isolates were predominantly from respiratory 
specimen especially endotracheal aspirate; their most common source was 
intensive care unit patients.  
 Efflux pump over expression followed by metalloβ-lactamase was the 
predominant mechanism for carbapenem resistance in P.aeruginosa while 
in A.baumannii, carbapenemase (oxacillinase type) production was the 
predominant mechanism. 
 Among the four MBL positive P.aeruginosa isolates, two isolates were 
positive for blaNDM-1gene and one isolate was positive for blaVIM gene. 
 Among the Carbapenemase producing A.baumannii, four isolates were 
positive for blaOXA-23 gene. 
 Carbapenem resistant isolates were also resistant to many other antibiotics 
but 100% susceptible to colistin. 
 Colistin MIC of four carbapenem resistant isolates was in the upper limit of 
susceptible range. 
Conclusion 
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CONCLUSION 
 
 Carbapenem resistance is increasing in the post-antibiotic era under the 
selection pressure of carbapenem in clinical settings. Detection of carbapenem 
resistant Pseudomonas aeruginosa and Acinetobacter baumannii has great impact 
on hospital infection control and for epidemiological purpose for the prevention of 
further spread of resistance in the community. To overcome the resistance, 
implementation of strict infection control practices and active surveillance of 
genes encoding carbapenemase are necessary.  
 
Because carbapenem resistance is also associated with resistance to 
antibiotics of other classes, the therapeutic options are very limited. Although 
colistin may be considered as an alternative for infections caused by carbapenem-
resistant Pseudomonas aeruginosa and Acinetobacter baumannii, MIC testing 
should be performed whenever clinical use of colistin is considered to contain the 
emerging colistin resistance. 
 
 
 
 
 
 
 
Colour plates 
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COLOUR PLATES 
 
 
Fig:10  Nitrate reduction test  
 
Positive control – Red colour eg. Escherichia coli 
False Negative  – No colour change even after addition of Zinc dust;  
  Arrow shows gas production. Eg.Pseudomonas aeruginosa 
True Negative  – Pink colour develops after adding zinc dust;  
  eg. Acinetobacter baumannii 
 
Positive 
False 
Negative 
True 
Negative 
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Fig : 11 AmpC betalactamase detection by combined disc method using cefoxitin 
(30µg) and cefoxitin + Phenylboronic acid (PBA) – 30/400 µg. Zone of inhibition 
around the inhibitor combination is ≥5mm than around the cefoxitin disc alone. 
 
 
Fig:12 MRIS – Meropenem Resistant Imipenem Sensitive phenotype of 
Carbapenem resistance in Pseudomonas aeruginosa 
  
CX + PBA 
CX 
AmpC β-lactamase detection 
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Fig:13Modified Hodge Test (MHT)  
A 54 & P 29 – MHT positive for carbapenemase production. 
Arrow shows Clover-leaf indentation 
 
Fig:14 Imipenem MIC detection by E-test showing MIC >32µg/ml (Carbapenem 
resistant A.baumannii – CRAB isolate) 
>32 µg/ml 
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Fig:15 Metallo Beta-Lactamase (MBL) detection by Combined disc method using 
Imipenem with Imipenem-EDTA (10/750µg/ml), Meropenem with Meropenem-EDTA 
(10/930µg/ml) & Ceftazidime with Ceftazidime-EDTA (10/930µg/ml) 
 
 
  
Fig:16 Colistin MIC by E-test for Carbapenem resistant Pseudomonas aeruginosa 
showing MIC of 1µg/ml (colistin sensitive) 
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Fig:17 Polymerase Chain Reaction (PCR) for the detection of blaOXA-23 gene in 
Carbapenemase producing Acinetobacter baumannii 
 
Lane 1- Non-template Control Lane2- DNALadder 
Lane 3,4,5 – A.baumannii isolates positive for blaOXA-23 gene  
Lane 6- Negative for blaOXA-23 gene 
 
 
 
Fig:18 Conventional PCR for the detection of blaNDM-1 gene in Metallo Beta 
Lactamase (MBL) producing Pseudomonas aeruginosa 
 
Lane 1- Non-template Control Lane 2- DNALadder  
Lane3,4 – P.aeruginosa isolates positive for blaNDM-1 gene 
1 2 3 4 5 6 
1 2 3 4 
 
475 bp 
453 bp 
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Annexures 
ANNEXURES 
PROFORMA 
 Name :                                                                      IP  NO: 
 Age:                                                                          Ward: 
 Sex: 
 Occupation: 
 Address: 
 Presenting complaints 
 Past history 
 Prior antibiotic  therapy 
 Clinical Diagnosis 
 Microbiological  investigation: 
 Direct examination : 
 Bacterial Culture : 
 Speciation 
 Antibiotic sensitivity pattern - 
 PCR for Carbapenemase genes – 
  
CONSENT FORM 
 
STUDY TITLE : Characterization and Colistin susceptibility of 
Carbapenem resistant isolates of  Pseudomonas aeruginosa and Acinetobacter 
baumannii in a tertiary care hospital  
I …………………………………………, hereby give consent to 
participate in the study conducted  by Dr.M.Sowndarya, Post graduate at Institute 
of Microbiology, Madras Medical College, Chennai and to use my personal 
clinical data and the result of investigations for the purpose of analysis and to 
study the nature of the disease, I also give consent to give my clinical Specimen 
(sputum, endotracheal aspirate, bronchial wash, pleural fluid, ascetic fluid, 
peritoneal dialysis fluid, wound swab, cerebrospinal fluid, urine, pus, blood) for 
further investigations. I also learn that there is no additional risk in this study. I 
also give my consent for my investigator to publish the data in any forum or 
journal. 
   
Signature/ Thumb impression                                   Place                             Date 
Of the patient/ relative 
 
Patient Name & Address: 
Signature of the investigator: 
  Signature of guide: 
 
INFORMATION SHEET 
STUDY TITLE : Characterization and Colistin susceptibility of 
Carbapenem resistant isolates of  Pseudomonas aeruginosa and Acinetobacter 
baumannii in a tertiary care hospital 
INVESTIGATOR  : Dr.M.Sowndarya, 
    Post Graduate, 
   Institute of Microbiology, 
 Madras Medical College, 
 Chennai - 600003 
GUIDE   : Dr. ThasneemBanu S M.D., 
    Professor, 
    Institute  of  Microbiology, 
    Madras  Medical  College, 
    Chennai - 600003 
 
 In recent times, infection caused by multidrug resistant organisms has 
become a great threat. Multidrug resistance is more common in non-fermenter 
gram-negative bacilli such as Pseudomonas aeruginosa and Acinetobacter 
baumannii. Carbapenems are the drug of choice for cephalosporin resistant gram-
negative bacterial infections. Carbapenem resistance is now an emerging threat. 
Therapeutic options for infections with these isolates include colistin. 
 I am going to detect the prevalence of carbapenem resistance among the 
isolates of Pseudomonas aeruginosa and Acinetobacter baumannii and their 
colistin susceptibility in this tertiary hospital. I am going to collect clinical 
specimens such as sputum, endotracheal aspirate, pleural fluid, bronchial wash, 
urine, blood and pus and process them accordingly. 150 patients are included in 
this study after getting informed consent. This study is entirely voluntary and 
patient can withdraw any time from this study. Extra cost will not be incurred to 
the patients. Any doubt regarding this study will be willingly clarified. Results of 
the study will be published. In case of any doubt please contact Dr.M.Sowndarya, 
Contact No:9442602762. 
  
S. 
No
Name Age Sex IP.No Ward Diagnosis Sample AMK GM CIP CAZ Cefepime PT IMP IMP MIC MRP Colistin
Resistance 
pattern
bla NDM-
1 /bla VIM
1 Selva 58 M 51229 Uro UTI Urine S S R R S S S - S - ESBL -
2 Muniyappan 56 M 49416 RTU UTI Urine R R R R R R S - R S MDR/MRIS -
3 Shobana 41 F 53551 Neuro
R 
Hemipleg
Urine R R R R R R S - R S MDR/MRIS -
4 Masthan 35 M 55166 RTU UTI Urine S S S R S S S - S - ESBL -
5 Manikandan 25 M 53465 Ortho
# R 
Femur
Urine S R R R R R R R R S MDR / MBL blaNDM-1
6 Bavani 42 F 55096 IMCU UTI Urine S S R R R S S - S - ESBL -
7 Dhandapani 45 M 51972 Nephro UTI Urine S S S S S S S - S - - -
8 Indira 45 F 50043 Uro UTI Urine R R R R S S S - S - MDR -
9 Gunasundari 57 F 50981 Uro UTI Urine S R S S S S S - S - - -
10 Devasagayam 45 M 51021 Nephro UTI Urine S S S S S S S - S - - -
11 Samynathan 37 M 54625 TM
Bronchie
ctasis
Sputum S R S R R R S - S - - -
12 Anandhan 46 M 53389 TM old PTB
Bronchial 
wash
S S S R S S S - S - - -
13 Padmini 45 F 51299 TM
Bronchie
ctasis 
Sputum S R R R R R S - S - MDR/AmpC -
14 Arumugam 40 M 51486 Ortho RTA Pus S S S S S S S - S - - -
15 Murugan 63 M 48846 SUR DFS Pus S S R R R S S - S - ESBL -
16 Kalidas 45 M 52132 Ortho RTA Pus S R S S S S S - S - - -
17 Bharani 35 M 52118 Ortho
BB 
Fracture
Pus S S S S S S S - S - - -
18 Shanmugam 46 M 53553 SUR
Liver 
abscess
Pus S S S R S S S - S - ESBL -
19 Subravelu 86 M 52389 SUR COPD Sputum S S S R R R S - S - ESBL -
20 Parthasarathy 54 M 56080 SUR DFS Pus S S S S S S S - S - - -
21 Kalaimani 55 M 41433 CT
Hydropn
eumotho
Pus S R S S S S S - S - - -
MASTER CHART - PSEUDOMONAS AERUGINOSA
S. 
No
Name Age Sex IP.No Ward Diagnosis Sample AMK GM CIP CAZ Cefepime PT IMP IMP MIC MRP Colistin
Resistance 
pattern
bla NDM-
1 /bla VIM
22 Annadurai 64 M 44821 RTU
Post 
renal 
Drain S S R R S S S - S - ESBL -
23 Anandhan 47 M 56067 VS
R AK 
Amputati
Pus S S S S S S S - S - - -
24 Rajesh 45 M 53852 Ortho
Compoun
d open # 
Pus S S R R S S S - S - - -
25 Siva 84 M 46003 CT
L 
Hydropn
Pus S S S R S S S - S - - -
26 Suryabalan 19 M 45307 Neuro RTA Urine R R R R R R S - R S MDR/MRIS -
27 Janaki 42 F 57750 ENT
Surgical 
site
Pus S S R R S S S - S - - -
28 Manikandan 19 M 43700 SUR Cellulitis Pus R R R R R S S - S - MDR/AmpC -
29 Vijendran 38 M 59071 IMCU
CKD/Lup
us 
Endotrac
heal 
S R R R R R S - R S MDR/MRIS -
30 Krishnamoorthy 45 M 54200 Neuro
RTA/hea
d injury
Endotrac
heal 
S S S R R R S - S - MDR/AmpC -
31 Sundaramoorthy 69 M 41178 SUR
Post 
operative 
Sputum S S S S S S S - S - - -
32 Kowsalya 25 F 57511 IMCU LRI Sputum S S S S S S S - S - - -
33 Radhi 47 F 56914 TM
Loculated 
effusion
Bronchial 
wash
S R S S S S S - S - - -
34 Sundaram 66 M 58674 Uro UTI Urine S R R R R R S - R S MDR/MRIS -
35 Janaki 42 F 57750 SUR
Non-
healing 
Pus S S S R S S S - S - ESBL -
36 Manikandan 18 M 43700 Ortho
BB 
Fracture
Pus R R R R R S S - S - MDR/ESBL -
37 Sathish 33 M 34903 Ortho
Crush 
injury
Pus R R R R R S S - S - MDR/ESBL -
38 Srinivasan 34 M 54770 Neuro
R 
Hemipleg
Sputum S S S R R S S - S - ESBL -
39 Natarajan 53 M 54809 Ortho LRI Sputum S S S S S S S - S - - -
40 Karthikeyan 57 M 52276 TM
Bronchie
ctasis
Bronchial 
wash
S S S S S S S - S - - -
41 Sampath 61 M 51273 MED LRI Sputum S S S R R R S - S - AmpC -
42 Ganesan 63 M 51375 SUR Old PTB Sputum S S S R R R S - S - AmpC -
43 Prakasam 85 M 57278 TM
CA R 
Lung
Bronchial 
wash
S S R R R R S - S - MDR/AmpC -
S. 
No
Name Age Sex IP.No Ward Diagnosis Sample AMK GM CIP CAZ Cefepime PT IMP IMP MIC MRP Colistin
Resistance 
pattern
bla NDM-
1 /bla VIM
44 Revathi 55 F 55864 SUR Cellulitis Pus S R S S S S S - S - - -
45 Srinivasan 46 M 52113 Ortho
Crush 
injury
Pus S S S S S S S - S - - -
46 Papammal 65 F 56866 SUR Cellulitis Pus S S R R S S S - S - - -
47 Sudhakar 43 M 49245 SUR
CA Buccal 
mucosa
Pus S S S S S S S - S - - -
48 Adhilakshmi 56 F 57561 SUR DFS Pus R R R R R S S - S - MDR -
49 Anbarasan 29 M 52579 Neuro
Paraplegi
a
Catheter 
tip
S S S R S S S - S - ESBL -
50 Siva kumar 38 M 58785 IMCU COPD Sputum S S R R R R S - S - MDR/AmpC -
51 Rajaram 70 M 59122 IMCU VAP
Endotrac
heal 
S S S R R R R R R S MDR/MBL blaVIM
52 Munusamy 35 M 58162 Ortho
Loculated 
effusion
Pleural 
fluid
R R R R R R R R R S MDR/MBL blaNDM-1
53 Nandhakumar 62 M 55777 MED
Pyothora
x
Pus S R S S S S S - S - - -
54 Chandran 50 M 58893 MED old PTB Sputum S R S S S S S - S - - -
55 Indra 47 F 58414 MED LRI Sputum S S S R R R S - S - ESBL -
56 Sowmya 19 F 59175 MED
Bronchie
ctasis
Sputum S S S R R R S - S - AmpC -
57 Krishnapillai 75 M 59563 Uro BPH Urine S S R R S S S - S - ESBL -
58 Kalyani 60 F 51273 ENT CSOM
Aural 
swab
S S S S S S S - S - - -
59 Pachaiyammal 50 F 57856 IMCU ARI
Endotrac
heal 
S R R R R R R I R S MDR/MBL Negative
60 Malarvizhi 61 F 51275 SUR
Wound 
infection
Pus S S S S S S S - S - - -
61 Jayalakshmi 51 F 48669 MED Cellulitis Pus S S R R S S S - S - - -
62 Rajkumar 37 M 58197 SUR DFS Pus S R S R R S S - S - ESBL -
63 Karthik 24 M 54445 MED
Pyothora
x
Pus S S S S S S S - S - - -
64 Nythirkani 40 F 51059 SUR Cellulitis Pus S S S S S S S - S - - -
65 Saravanan 25 M 48518 Ortho # Femur Pus S R R S S S S - S - - -
S. 
No
Name Age Sex IP.No Ward Diagnosis Sample AMK GM CIP CAZ Cefepime PT IMP IMP MIC MRP Colistin
Resistance 
pattern
bla NDM-
1 /bla VIM
66 Kavitha 18 F 43769 MED LRI Sputum S S S R S S S - S - - -
67 Sampath 70 M 42759 ENT Stridor Pus S S S S S S S - S - - -
68 Mahendran 26 M 51066 Ortho
# BB 
forearm
Pus R R R R R S S - S - MDR/ESBL -
69 Venkatakrishna 27 M 52381 Nephro CKD
Catheter 
tip
S S S S S S S - S - - -
70 Annadurai 41 M 52600 TM
Bronchie
ctasis
Sputum S S S R R R S - S - MDR/AmpC -
71 Ekambaram 65 M 44162 IMCU VAP
Endotrac
heal 
R R S R R R S - S MDR -
72 Sundari 40 F 56107 Nephro CKD PD Fluid S S R R S S S - S - - -
73 Ranjith 45 M 51609 ENT CSOM
Aural 
swab
R R R R R R S - S - MDR/AmpC -
74 Karthik 32 M 52133 VS Trauma Pus S S R R R S S - S - ESBL -
75 Philomina 60 F 51072 TM old PTB Sputum S S S R R R S - S - AmpC -
S. 
NO
Name Age Sex IP.No Ward Diagnosis Sample AMK GM CIP CAZ PT COT TET IMP
IMP 
MIC
MRP Colistin
Resistance 
pattern
PCR for 
OXA-23
1 Jayaraman 80 M 51230 GICU UTI Urine S R R R S R R S - S - MDR/ESBL -
2 Veeramani 42 M 54778 VS
Skin 
Graft
Pus R R R R S R S S - S - MDR/ESBL -
3 Lakshmi 56 F 51287 MED UTI Urine S R R S S S R S - S - - -
4 Umapathy 21 M 57156 Uro UTI Urine S S S R S S R S - S - ESBL -
5 Mahamathi 58 M 56345 Uro UTI Urine S S R S S R S S - S - - -
6 Venkatesan 45 M 48919 SUR DFS Pus S R R R R R R S - S - MDR/AmpC -
7 Sivakumar 65 M 54215 SUR
Carbuncl
e
Pus R R S S S R S S - S - - -
8 Shanmugam 55 M 53496 VS Cellulitis Pus S R S R S R S S - S - ESBL -
9 Elammal 60 F 36945 NS
RTA/hea
d injury
Endotrac
heal 
S S S R S R R S - S - ESBL -
10 Janarthanan 80 M 53908 MED Sepsis Blood S R S R R R R R I R S MDR/MBL Negative
11 Rekha 30 F 54375 SUR RTA Pus S R R R R R S S - S - MDR/AmpC -
12 Selvam 65 M 47882 GICU Sepsis Blood S S S R S R R S - S - - -
13 Kuruvammal 33 F 52114 Uro UTI Urine S R R R R S R S - S - MDR/AmpC -
14 Sathish Kumar 29 M 50218 Ortho # Femur Pus R R R R R R R S - S - MDR/AmpC -
15 Sathish 31 M 52689 Uro
Pyelonep
hritis
Urine S R R S S S R S - S - - -
16 Ponni 73 F 56284 MED UTI Urine S R R R S R S S - S - MDR/ESBL -
17 Dinesh Kumar 23 M 50533 Ortho RTA Pus S R R R S R R S - S - MDR -
18 Padmavathy 52 F 58243 CT SSI Pus R S S R S R S S - S - ESBL -
19 Ramesh 55 M 40851 Uro
Pyonephr
itis
Urine R S R R S R R S - S - MDR -
20 Kishore 18 M 33932 Ortho
# Left 
Tibia
Pus S S S R S R R S - S - ESBL -
21 Geetha 19 F 55256 Ortho
# 
Humerus
Pus S R S S S S S S - S - - -
MASTER CHART - ACINETOBACTER BAUMANNII
S. 
NO
Name Age Sex IP.No Ward Diagnosis Sample AMK GM CIP CAZ PT COT TET IMP
IMP 
MIC
MRP Colistin
Resistance 
pattern
PCR for 
OXA-23
22 Poovarasan 18 M 57505 IMCU Urosepsis Blood R R R R R R R R R R S MDR/CRAB Positive
23 Angiah 43 M 56538 MED UTI Urine S R S R S R S S - S - ESBL -
24 Gayathri 19 F 55744 SUR UTI Urine S S R R S R R S - S - ESBL -
25 Anandha sekar 70 M 57820 Uro BPH Urine S R S R S R S S - S - - -
26 Kumaresan 22 M 57941 MED
Bronchie
ctasis
Sputum S S S R S R S S - S - - -
27 Surya 19 M 57935 SUR SSI Pus S R R R R R R S - S - MDR/AmpC -
28 Suresh 32 M 54344 NS
Ganglioc
apsular 
Endotrac
heal 
S R S R R R R S - S - MDR/AmpC -
29 Rajendran 58 M 56916 TM Old PTB Sputum S S S R S S R S - S - ESBL -
30 Kalaivani 55 F 56639 MED
Bronchie
ctasis
Sputum R R S R R R R R R R S MDR/MBL -
31 Dhanalakshmi 24 F 57928 MED UTI Urine R R R R S R S S - S - MDR/ESBL -
32 Manikandan 27 M 53109 Nephro CKD Urine S R S S S R S S - S - - -
33 Krishnan 62 M 58743 SUR DFS Pus R R R R S S R S - S - MDR/ESBL -
34 Karthik 27 M 58796 SUR
Abdomin
al injury
Pus S R S S S S S S - S - - -
35 Arumugam 67 F 59197 IMCU VAP
Endotrac
heal 
R R R R R R S R R R S
MDR/AmpC/
MBL
Negative
36 Prasad 48 M 57529 IMCU VAP
Endotrac
heal 
S R R R R R S R R R S MDR/CRAB Positive
37 Nagaraj 45 M 59476 TM COPD Sputum S S S R S R R S - S - ESBL -
38 Jayachandran 30 M 55436 Nephro CKD PD Fluid S S S S S R S S - S - - -
39 Natraj 32 M 53487 RTU
Post 
renal 
Drain S R S R S R R S - S - ESBL -
40 Soundarajan 60 M 52762 IMCU VAP
Endotrac
heal 
R R R R R R R R R R S
MDR/CRAB/
AmpC
Positive
41 Anjalai 48 F 51279 CT MVR Pus S S R R S R R S - S - - -
42 Vel 26 M 50062 SUR
Scrotal 
abscess
Pus R R R R S R R S - S - MDR/ESBL -
43 Kalyani 45 F 54113 SUR RTA Pus R R R R S R S S - S - MDR/ESBL -
S. 
NO
Name Age Sex IP.No Ward Diagnosis Sample AMK GM CIP CAZ PT COT TET IMP
IMP 
MIC
MRP Colistin
Resistance 
pattern
PCR for 
OXA-23
44 Mal Cruz 65 M 53104 SUR Cellulitis Pus R R R R S R R S - S - MDR/ESBL -
45 Valarmathi 39 F 52869 Nephro CKD
Catheter 
tip
S R S R S R S S - S - - -
46 Chinnapillai 70 M 45637 Uro BPH Urine S R R S S S R S - S - - -
47 Kalyani 75 F 42739 TM
Pleural 
effusion
Sputum S R S R S R R S - S - - -
48 Manikandan 33 M 41329
Hepatolo
gy
DCLD
Ascitic 
fluid
S R S S S S S S - S - - -
49 Selvam 54 M 55241 IMCU VAP
Endotrac
heal 
R R R R R R R R R R S
MDR/CRAB/
AmpC
Positive
50 Srinivasan 70 M 53621 MED LRI Sputum S S S R R R S S - S - ESBL/AmpC -
51 Arumugam 45 M 51025 NS RTA
Endotrac
heal 
R R R R S R R S - S - MDR/ESBL -
52 Murugesan 50 M 53126 Nephro CKD PD Fluid S S S S S R S S - S - - -
53 Sivasankar 47 M 43789 RTU
Post 
renal 
Drain R R S R R R R S - S -
MDR/ESBL/
AmpC
-
54 Narasiman 66 M 45762 IMCU Sepsis Blood R R R R R R R R I R S MDR/CRAB Negative
55 Rafi 19 M 48743 NS
RTA/hea
d injury
Endotrac
heal 
S R R R R R S S - S - MDR/AmpC -
56 Dhanakarthi 35 M 56735 MED UTI Urine S R R R R R S S - S - MDR/AmpC -
57 Elumalai 45 M 53478 MED PTB Sputum S S S R S R S S - S - ESBL -
58 Vadivukarasi 18 F 56790 IMCU AIHA Blood S R R R R R R S - S - MDR/AmpC -
59 Sophia 22 F 59459 ISCU
Appendic
ular 
Blood S R R R R R S S - S - MDR -
60 Vadivel 36 M 59466 CT VAP
Endotrac
heal 
R S R R R R R S - S - MDR/AmpC -
61 Philomina 60 F 52373 GICU LRI Sputum S S S S S R S S - S - ESBL -
62 Kalyani 75 F 58760 MED
Pleural 
effusion
Sputum S S S R S S S S - S - - -
63 Manikandan 33 M 58158
Hepatolo
gy
DCLD
Ascitic 
fluid
S R S S S S S S - S - - -
64 Kanagaraj 22 M 57389 Ortho # BB leg Pus S S S R R R R S - S - AmpC -
65 Savithri 40 F 59226 CT
LA 
Myxoma
Urine R R R R R R R R R R S MDR/CRAB Negative
S. 
NO
Name Age Sex IP.No Ward Diagnosis Sample AMK GM CIP CAZ PT COT TET IMP
IMP 
MIC
MRP Colistin
Resistance 
pattern
PCR for 
OXA-23
66 Ranjith 45 M 56438 Ortho # BB leg Pus R R R R S R S S - S - MDR/ESBL -
67 Vasantha 55 F 48762 MED UTI Urine S S S R R R S S - S - AmpC -
68 Ekambaram 65 M 55487 NS
Head 
injury
Endotrac
heal 
R R R R R R S S - S - MDR/AmpC -
69 Venkatakrishna 27 M 53286 MED LRI Sputum S R S S S R S S - S - - -
70 Sundari 40 F 57890 Nephro CKD PD Fluid S R S R S R S S - S - ESBL -
71 Saroja 65 F 49875 ISCU SSI Pus S R R R S S S S - S - MDR/ESBL -
72 Narimani 68 F 56742 IMCU
Stridor/V
AP
Endotrac
heal 
R R R R R R R R R R S MDR/CRAB Negative
73 Swaminathan 68 M 54677 MED LRI Sputum R R R R S R S S - S - MDR/ESBL -
74 Ramesh 37 M 53771 Nephro Cellulitis Pus S S R R S R R S - S - - -
75 Tamilarasi 40 F 52651 NS RTA Urine S R S R R S S S - S - MDR/AmpC -
LEGENDS FOR MASTER CHART 
 
# BB   – Fracture both bone 
AMK   –  Amikacin 
AmpC  –  AmpC Beta-lactamase 
ARI   –  Acute Respiratory Illness 
BPH   –  Benign Prostatic Hypertrophy 
CAZ   –  Ceftazidime 
CIP   –  Ciprofloxacin 
COPD  –  Chronic Obstructive Pulmonary Disease 
COT   –  Trimethoprim-sulfamethoxazole 
CRAB  –  Carbapenem resistant A.baumannii 
CSOM  –  Chronic Suppurative Otitis Media 
CT   –  cardiothoracic unit 
DFS   –  Diabetic Foot Syndrome 
ESBL  –  Extended Spectrum Beta-lactamase 
GICU  –  Geriatric Intensive care unit 
GM   –  Gentamicin 
I   –  Intermediate 
IMCU  –  Intensive Medical care unit 
IMP   –  Imipenem 
ISCU   –  Intensive Surgical care unit 
LRI   –  Lower Respiratory tract Infection 
MBL   –  Metallo Beta-lactamase 
MDR   –  Multidrug Resistant 
MED   –  Medicine 
MIC   –  Minimum Inhibitory Concentration 
MRIS  –  Meropenem Resistant Imipenem Sensitive 
MRP   –  Meropenem 
NDM-1  –  New Delhi Metallo Beta-lactamase 
Nephro –  Nephrology 
NS   –  Neurosurgery 
Ortho   –  Orthopedics 
OXA  –  Oxacillinase gene 
PT   –  Piperacillin-tazobactam 
PTB   –  Pulmonary Tuberculosis 
R   –  Resistant 
RTA   –  Road Traffic Accident 
RTU   –  Renal Transplant Unit  
S   –  Sensitive 
SUR   – Surgery 
TET   –  Tetracycline 
TM   –  Thoracic Medicine 
Uro  –  Urology 
UTI   –  Urinary Tract Infection 
VAP   –  Ventilator Associated Pneumonia 
VIM   –  Verona Integron mediated Imipenemase 
VS   –  Vascular Surgery 
  
